

# Cumulative Index 1988

Volume 72

---

<i>January</i>	CARDIOVASCULAR PHARMACOTHERAPY I, pages 1-274
<i>March</i>	CARDIOVASCULAR PHARMACOTHERAPY II, pages 275-554
<i>May</i>	UPDATE ON ANTIBIOTICS II, pages 555-743
<i>July</i>	ANXIETY AND DEPRESSION, pages 745-977
<i>September</i>	DIFFICULT DIAGNOSES, pages 979-1270
<i>November</i>	DIABETES MELLITUS, pages 1271-1607

---

Note: Page numbers of articles and issue titles are in **boldface** type.

- Abscess, perinephric. See *Perinephric abscess*.  
 fever of, 1251
- Acebutolol, 40, 297-298  
 antiarrhythmic effects of, 59, 298  
 dosages for, 279, 298  
 drug interactions of, 298  
 electrophysiologic actions of, 281, 297  
 hemodynamic effects of, 281, 298  
 immunologic effects of, 72  
 indications for, 281, 298  
 metabolism of, 279, 297-298  
 partial agonist activity of, 44  
 pharmacokinetics of, 279, 297-298  
 selectivity of, 43  
 side effects of, 281, 298
- Acyclovir, 691-697  
 dosages for, 697  
 indications for, 695-697  
 mechanism of action of, 692  
 pharmacokinetics of, 692-694  
 side effects of, 694-695  
 toxicity of, 694-695
- Adenomas, adrenal gland. See *Adrenal gland, adenomas of*.  
 thyroid gland. See *Thyroid gland, adenomas of*.
- Adenosine, 308-309  
 antiarrhythmic effects of, 308-309  
 dosages for, 279, 309  
 drug interactions of, 309  
 electrophysiologic actions of, 281, 308  
 hemodynamic effects of, 281, 308  
 indications for, 281, 309  
 metabolism of, 279, 308  
 pharmacokinetics of, 279, 308  
 side effects of, 281, 309
- Adjustment disorders, anxious mood and, 746  
 depressed mood and, 745, 836-837, 839
- Adrenal gland, adenomas of, 1117  
 computerized tomography of, 1126  
 differential diagnosis of, 1124-1126  
 radionuclide imaging of, 1126-1127  
 venous hormone sampling for localization of, 1127
- carcinoma of, 1124  
 cortical disorders of. See *Hyperaldosteronism*.
- Adrenergic blockers, alpha. See *Alpha-adrenergic blockers*.  
 beta-adrenergic. See *Beta-adrenergic blockers*.
- Adriamycin cardiotoxicity, 250
- Agoraphobia, alcoholism and, 876-877, 879  
 diagnosis of, 759  
 panic disorder and, 759

- AIDS, antiviral agent therapy for, 704-711  
 AL 721, 708  
 AZT and, 705-709  
 combination therapy of, 708-709  
 DDC, 709  
 HPA-23, 707-708  
 hybridons, 708  
 immunomodulators and, 709  
 interferons and, 709-711  
 phosphonoformic acid, 708  
 ribavirin, 707  
 suramin, 707  
 interferon therapy for, 709-711  
 AL 721, 708  
 Albendazole, 674-675  
 Alcoholism, 1133-1153  
 anxiety disorders associated with, 875-879  
 cirrhosis of liver and, 1146  
 cognitive deficits and, 1145  
 comorbidity of, 869  
 depression associated with, 872-874, 878-879  
 diagnosis of, 1134-1148  
 approach to, 1134-1136  
 laboratory tests for, 1136-1142, 1147  
 questionnaires for, 1142-1144, 1147-1148  
 signs and symptoms for, 1144-1146  
 epidemiology of, 868, 1133-1134  
 family history of, 1134, 1146  
 fetal alcohol syndrome and, 1145-1146  
 gastritis and, 1145  
 genetic factors of, 1134, 1146  
 Hilton Drinking Behavior Questionnaire  
 for evaluation of, 1144  
 hypertension and, 1145  
 laboratory tests of, 1136-1142, 1147  
 alkaline phosphatase, 1139  
 aspartate transaminase, 1139  
 blood alcohol concentration, 1141  
 combination blood tests, 1141-1142  
 gamma glutamyltransferase, 1137-1138  
 high-density lipoprotein cholesterol, 1140  
 liver function, 1139-1140  
 mean corpuscular volume, 1138-1139  
 triglyceride, 1140  
 uric acid, 1140  
 Michigan Alcohol Screening Test for, 1143-1144  
 Minnesota Multiphasic Personality Inventory for, 1144  
 mood changes from, 871  
 nervous system effects of, 1145  
 pancreatitis and, 1146  
 pregnancy complications of, 1145-1146  
 psychiatric disorders and, 1146  
 psychopathology associated with, 870-871  
 questionnaires for evaluation of, 1143-1144, 1147-1148  
 suicidal behavior and, 945  
 treatment of, 878-879  
 Aldosterone, increased secretion of. See *Hyperaldosteronism*.  
 Allergic vasculitis, 1254  
 Allopurinol, ischemic/reperfused myocardium drug therapy and, 233-234  
 Alper's disease, 252  
 Alpha-adrenergic blockers, 188, 189-190, 427-440  
 alpha-adrenergic receptors and, 427-428  
 dosages for, 435-436  
 indications for, 430-435  
 angina and, 432-433  
 arrhythmias and, 433  
 arterioconstriction and, 435  
 bronchospasm and, 434  
 congestive heart failure and, 431-432  
 hypertension and, 386-387, 390, 430-431  
 lung disease and, 434-435  
 pheochromocytoma and, 433-434  
 prostatic obstruction and, 435  
 pulmonary hypertension and, 434-435  
 shock and, 434  
 nonselective, 428-429  
 selective, 429  
 silent myocardial ischemia drug therapy and, 188, 189-190  
 structure of, 427-428  
 types of, 428-430  
 Alprazolam, 826, 900  
 Alveolar proteinosis, 1239  
 Amantadine, 703-704  
 dosages for, 704  
 indications for, 704  
 mechanism of action of, 703  
 pharmacokinetics of, 703  
 side effects of, 703-704  
 spectrum of activity of, 703  
 toxicity of, 703-704  
 Amikacin, 601-602  
 Aminoglycoside antibiotics, 581-612  
 absorption of, 589  
 artificial kidney clearance of, 593  
 chemistry of, 588-589  
 comparative analysis of, 600-602  
 amikacin and, 601-602  
 gentamicin and, 601  
 kanamycin and, 601  
 neomycin and, 600  
 netilmicin and, 601  
 streptomycin and, 600  
 tobramycin and, 601  
 cost of, 597-598  
 distribution of, 589  
 dosing of, 590-593  
 excretion of, 590  
 future of, 602-603  
 indications for, 598-602

- mechanism of action of, 582-583
- pharmacokinetics of, 589-594
- pharmacology of, 589-590
- resistance to, 583-585
- serum assays of, 597
- spectrum of activity of, 585-587
- toxicity of, 595-597
- Aminoquinolones, 684-686
- Amiodarone, 302-305, 321-358
  - anti-ischemic effects of, 324-325
  - antiarrhythmic effects of, 303, 328-334
  - bioavailability of, 325-327
  - cardiac effects of, 338
  - cardioversion and, 343
  - cutaneous effects of, 339
  - distribution of, 325-327
  - dosages for, 279, 304-305, 344-345
  - drug interactions of, 304, 342-343
  - electrophysiologic actions of, 281, 302, 322-323
  - elimination of, 325-327
  - epididymitis from, 341
  - gastrointestinal effects of, 341
  - hemodynamic effects of, 281, 303, 323-324
  - historical background of, 302
  - immunologic effects of, 341-342
  - indications for, 281, 304-305, 328-334
    - atrial ectopic tachycardia and, 330
    - atrial fibrillation-flutter and, 329
    - bradycardia-tachycardia syndrome and, 330
    - paroxysmal AV reentrant supraventricular tachycardia and, 329-331
    - paroxysmal atrial fibrillation and, 331
    - supraventricular arrhythmias and, 329-331
    - ventricular arrhythmias and, 331-334
  - metabolism of, 279, 302-303, 325-328
  - neuromuscular effects of, 338-339
  - ocular effects of, 341
  - open heart surgery and, 343
  - pharmacokinetics of, 279, 302-303, 325-328
  - pregnancy and, 343
  - pulmonary toxicity of, 335-338
  - side effects of, 281, 303-304, 334-342
  - structure of, 321, 322
  - therapeutic serum concentrations of, 327-328
  - thyroid dysfunction from, 339-341
- Amlodipine, 489
- Amoxapine, 820
- Amphotericin B, 644-648
  - indications for, 645
  - mechanism of action of, 644-645
  - pharmacokinetics of, 645-646
  - toxicity of, 646-648
- Amylodosis, 1163, 1237
- Anesthesia, nitrates used in conjunction with, 23
- Angina pectoris, 13-19
  - alpha-adrenergic blocker therapy for, 432-433
  - antiplatelet drug therapy for, 151-157, 194-195
  - beta-adrenergic blocker therapy for, 50, 54-56, 63
    - mechanism of action of, 38
    - silent myocardial ischemia and, 188-190
  - calcium channel blockers for, 90-93, 190-193
    - beta-adrenergic blockers combined with, 55, 91-92
    - mechanism of action of, 90
    - stable angina and, 91-92
    - unstable angina and, 92-93
    - variant angina and, 93
  - classification of, 13-19
  - coenzyme Q10 for, 246-248
  - combination drug therapies for, 194
    - calcium-entry blockers and beta-blockers, 55, 91-92
    - nitrates and beta-blockers, 55, 92
  - diltiazem therapy for, 473-476
  - mixed, 17
  - nicardipine therapy for, 485
  - nifedipine therapy for, 463
  - nitrate drug therapy for, 186-188
    - beta-adrenergic blockers with, 55
    - formulations of, 24, 26
    - historical background of, 1, 13
    - mechanism of action of, 5
    - recommendations for usage of, 30
    - tolerance to, 29
    - type of anginal syndrome as factor in, 13-19
  - platelets in, role of, 126
  - silent myocardial ischemia and. *See Silent myocardial ischemia, angina pectoris and.*
  - stable, 13
    - antiplatelet drug therapy for, 151-153
    - beta-adrenergic blockers for, 54-55
    - calcium channel blockers for, 91-92
    - nitrates for, 13-17
  - unstable, 17-19
    - antiplatelet drug therapy for, 153-157
    - beta-adrenergic blockers for, 55-56
    - calcium channel blockers for, 92-93
    - nitrates for, 17-19
  - vasospastic, 19
    - beta-adrenergic blockers for, 55-56
    - calcium channel blockers for, 93
    - nitrates for, 19
  - verapamil therapy for, 468
- Angiodysplasia, gastrointestinal, 1171-1172

- Angioplasty, percutaneous transluminal coronary. See *Percutaneous transluminal coronary angioplasty*.
- Angiotensin-converting enzyme inhibitors, 388-389, 399-425
- absorption of, 404-405
  - adverse effects of, 410-413
  - cardiovascular effects of, 401-403
  - comparative analysis of, 413-414
  - congestive heart failure therapy and, 408-410, 415
  - distribution of, 405
  - dosages for, 414-415
  - drug interactions of, 413
  - elimination of, 405-406
  - hemodynamic effects of, 401-404
  - historical background of, 399-400
  - hormonal effects of, 404
  - hypertension drug therapy and, 388-390, 406-408, 415
  - indications for, 406-410
  - metabolism of, 405
  - neural effects of, 403-40
  - pharmacokinetics of, 404-406
  - protein-binding of, 405
  - renal effects of, 403
  - structure of, 400-401
- Antianginal drug therapy, 185-196
- antiplatelet activity of, 131-135
  - beta-adrenergic blockers in. See *Beta-adrenergic blockers*.
  - calcium channel blockers in. See *Calcium channel blockers*.
  - nitrates in. See *Nitrates*.
- Antiarhythmic drugs, 275-319
- acebutolol and, 279, 281, 297-298
  - adenosine and, 279, 281, 308-310
  - alpha-adrenergic blockers and, 433
  - amiodarone. See *Amiodarone*.
  - beta-adrenergic blockers for, 50, 56-59
  - calcium channel blockers for, 99-101
  - cibenzoline and, 276-282
  - classification of, 275, 276
  - coenzyme Q10 for, 252
  - encainade and, 278, 280, 288-291
  - esmolol and. See *Esmolol*.
  - ethmozin and, 278, 280, 286-288
  - flecainide and, 278, 280, 291-293
  - lorcainide and, 278, 280, 293-294
  - mexiletine and, 278, 280, 284-286
  - pirmenol and, 278, 280, 282-283
  - propafenone and, 278, 280, 294-297
  - sotalol and, 279, 281, 301-302
  - tocainide and, 278, 280, 283-284
  - verapamil and, 279, 281, 305-308
- Antibiotics, aminoglycoside. See *Aminoglycoside antibiotics*.
- aztreonam. See *Aztreonam*.
  - eye infection. See *Eye infection, antimicrobial/antibiotic therapy for*.
  - fungus infection. See *Antifungal agents*.
  - imipenem. See *Imipenem*.
  - metronidazole. See *Metronidazole*.
  - osteomyelitis. See *Osteomyelitis, antibiotic therapy for*.
  - parasitic infection. See *Parasitic infections, antimicrobial agents for*.
  - quinolone. See *Quinolones*.
  - topical. See *Topical antibiotics*.
  - tuberculosis. See *Tuberculosis, drug therapy for*.
  - viral infection. See *Antiviral agents*.
- Antifungal agents, 637-659
- amphotericin B, 644-648
  - aspergillosis therapy and, 658
  - blastomycosis therapy and, 654
  - candidiasis therapy and, 639-643, 657-658
  - ciclopirox olamine, 638
  - coccidioidomycosis therapy and, 655-656
  - combination therapy of, 644
  - cryptococcosis therapy and, 656-657
  - flucytosine, 648-650
  - future of, 658-659
  - haloprogin, 637-638
  - histoplasmosis therapy and, 655
  - in vitro susceptibility testing and, 644
  - ketoconazole, 652-654
  - miconazole, 650-652
  - miconazole, 638-639
  - phycomycosis therapy and, 658
  - pseudoallescheriosis therapy and, 656
  - sporotrichosis therapy and, 654
  - systemic, 643-644
  - topical, 637-643
- Antihypertensive drugs, 373-397
- adrenergic blockers and, 384-387, 390-391
  - alpha, 386-387, 430-431
  - beta, 365-366, 384-387
  - angiotensin-converting enzyme inhibitors and, 388-390, 406-408, 415
  - calcium channel blockers and. See *Calcium channel blockers*.
  - centrally-acting sympatholytic drugs and, 390
  - diabetes mellitus and, 1408-1410
  - diuretics and, 381-384
  - elderly patient therapy and, 537-544
  - efficacy of, 541-544
  - recommendations for, 541-544
  - safety of, 537-541
  - esmolol and, 365-366
  - ketanserin and. See *Ketanserin*.
  - terazosin and. See *Terazosin*.
  - vasodilators and. See *Vasodilators*.
- Antimoniotungstate, 707-708
- Antinuclear antibodies, beta-adrenergic blocker-induced development of, 72

- Antiplatelet drugs, 117, 127-171  
 antianginal drugs as, 131-135  
 arachidonate acid pathway inhibitors as, 127-131  
 aspirin as. See *Aspirin*.  
 calcium channel antagonists as, 134-135  
 clofibrate as, 136  
 cyclo-oxygenase inhibitors as, 128-130  
 dipyridamole as. See *Dipyridamole*.  
 indications for use of, 137-171  
   angina pectoris and, 151-157  
   aortocoronary bypass graft patency maintenance and, 157-165  
   coronary angioplasty restenosis prevention and, 166-167  
   coronary thrombolysis and, 167  
   myocardial infarction prevention and, 137-151  
 ketanserin as, 136  
 mechanism of action of, 127-131  
 nitrates as, 133  
 pentoxifylline as, 136  
 phospholipase inhibitors as, 127-128  
 propranolol as, 131-133  
 prostacyclin as, 131  
 sulfinpyrazone as. See *Sulfinpyrazone*.  
 thromboxane synthetase inhibitors as, 130  
 ticlopidine as, 135
- Antiviral agents, 691-714  
 acyclovir. See *Acyclovir*.  
 AL 721, 708  
 amantadine, 703-704  
 anti-HIV, 704-711  
 antimoniotungstate, 707-708  
 azidothymidine, 705-709  
 DDC, 709  
 DHPG, 702-703  
 HPA-23, 707-708  
 hybridons, 708  
 immunomodulators, 709  
 interferons, 709-711  
 phosphonoformic acid, 708  
 ribavirin, 698-700, 707  
 rimantadine, 704  
 suramin, 707  
 tissue paper impregnated with, 711  
 vidarabine, 700-702  
 WIN compounds, 711
- Anxiety disorders, 746  
 adjustment disorder with, 746  
 alcoholism and, 875-879  
 benzodiazepine abuse and, 877  
 biologic basis for, 791-813  
 childhood, 757-758  
 cocaine abuse and, 877  
 cost considerations of, 747  
 diagnosis of, 747-749, 753-754, 757-762  
   adult disorders and, 758-762  
   behavioral/motoric methods of, 915  
 childhood disorders and, 757-758  
 MMPI for, 912  
 physiological methods of, 915  
 psychological tests for, 911-915  
 Rorschach test for, 912  
 self-report methods of, 913-915  
 drug-resistant, 987-909  
   misdiagnosis and, 903-904  
   prediction of, 901-904  
   principles of, 897-901  
   reasons for, 903-904  
 drug therapy for, 815-816, 823-828, 921-922  
   alprazolam and, 826, 900  
   barbiturates and, 825-826  
   benzodiazepines and, 823-825, 898-900,  
     beta-adrenergic blockers and, 826-827, 898  
   buspirone and, 827, 900-901  
   meprobamate and, 825-826  
   shorter vs longer-acting drugs, 898  
 epidemiology of, 747, 868  
 generalized. See *Generalized anxiety disorder*.  
 obsessive-compulsive disorder and, 746, 759-760  
 panic disorder and. See *Panic disorder*.  
 phobias and. See *Phobias*.  
 psychiatric consultation for, 929-934  
   liaison services for, 933-934  
   process of, 930-931  
   reasons for, 931-933  
   referral vs, 929-930  
 psychological assessment of, 911-915  
 psychotherapy for, 917-918, 920-922  
   approach-withdrawal theory for, 918  
   avoidance theories for, 917-918  
   behavioral models of, 917-918  
   cognitive theories for, 917-918  
   combination drug therapy with, 921-922  
   comparative analysis of, 921  
   drug therapy vs, 921-922  
   effectiveness of, 920-922  
   no therapy vs, 920-921  
   respondent theories for, 917  
 sedative abuse and, 877  
 stimulant abuse and, 877  
 substance abuse and, 867, 869, 875-879  
 treatment of, barriers to, 748-749  
   drug therapy, 815-816, 823-828, 921-922  
   goals of, 749-750  
   psychotherapy, 917-918, 920-922  
   referrals for, 748  
   substance abuse and, 878-880
- Aortic aneurysm, geriatric patient 1220-1221

- Aortic stenosis, silent myocardial ischemia and, 1034  
sudden death from, 1026
- Aortocoronary bypass surgery, 157-165  
graft and anastomoses occlusion after, 157-158  
antiplatelet drug therapy for prevention of, 158-165  
atherosclerosis in, role of, 158-159  
platelets in, role of, 158
- Appendicitis, geriatric patient 1218
- Arachidonate acid pathway, inhibition of, 127-131  
cyclo-oxygenase inhibitors in, 128-130  
phospholipase inhibitors in, 127-128  
thromboxane synthetase inhibitors in, 130-131  
oxygen-derived free radical damage to myocardium and, 229
- Arrhythmias, drug therapy for. See *Antiarrhythmic drugs*.
- Arteriovenous malformations, gastrointestinal, 1172
- Aspergillosis, 658, 1077-1078
- Aspirin, 128  
antiplatelet activity of, 128-130, 168-171  
cyclo-oxygenase inhibition via, 128-130  
indications for use of, angina pectoris and, 151, 155-157, 194-195  
aortocoronary bypass graft patency maintenance and, 158-165  
coronary angioplasty restenosis prevention and, 166-167  
coronary thrombolysis and, 167  
myocardial infarction and, 137-148  
myocardial ischemia and, 194-195, 236  
mechanism of action of, 128-130  
thrombolytic therapy with, 167
- Asthma, calcium channel blockers for, 102-103
- Atenolol, 40  
angina pectoris drug therapy and, 189  
geriatric usage of, issues of, 49  
myocardial infarction drug therapy and, 60  
myocardial ischemia drug therapy and, 189  
Raynaud's phenomenon from, 69  
selectivity of, 43
- Atherosclerosis, antiplatelet drug therapy for, 168-171  
aortocoronary bypass surgery failure due to, 158-159  
diabetes mellitus and. See *Diabetes mellitus, atherosclerosis and*.  
nitrate drug therapy for, 9, 10  
platelets in, role of, 124-126
- Atrial fibrillation, beta-adrenergic blockers for, 58-59
- Atrial flutter, beta-adrenergic blockers for, 58
- Avoidant disorder, 757
- Azidothymidine (AZT), 705-709  
adverse reactions to, 705-706  
clinical trials on, 706-707  
combination therapy with, 708-709  
dosages for, 707  
indications for, 707  
pharmacokinetics of, 705  
toxicity of, 705-706
- Aztreonam, 555-566  
adverse effects of, 561-562  
dosages for, 562-563  
indications for, 559-561  
bone and joint infections and, 561  
central nervous system infections and, 561  
gynecologic infections and, 561  
intra-abdominal infections and, 561  
respiratory infections and, 560  
septicemia and, 560-561  
sexually transmitted infections and, 561  
skin infections and, 561  
urinary tract infections and, 560  
mechanism of action of, 555  
pharmacokinetics of, 558-559  
resistance to, 557  
spectrum of activity of, 556-557
- Barbiturates, 825-826
- Benzodiazepines, abuse of, anxiety disorder from, 877  
depression from, 875  
agonists and antagonists of, 793-794  
anxiety disorder treatment with, 792-797, 823-825, 898-900  
generalized anxiety disorder and, 901  
panic disorders and, 804-805  
buspirone vs, 796-797  
mood changes from, 872  
pharmacology and pharmacokinetics of, 792-793, 900  
receptors for, 794-795  
resistance to effects of, 901  
withdrawal reactions to, 899-900
- Bepridil, 99
- Beta-adrenergic blockers, 37-73, 359-372, 384-387  
adverse effects of, 67-72  
agonist activity of, partial, 44-45  
alpha-adrenergic activity of, 45  
antinuclear antibody development from, 72  
atrioventricular conduction delay from, 68  
baroreceptor effect of, 53  
blood pressure effects of, 50-54, 71-72  
cardiovascular effects of, 50-63  
central nervous system effects of, 51, 71  
chronotropic effects of, negative, 51  
drug interactions of, 70-72

- electrophysiologic effects of, 56-57  
 esmolol and. See *Esmolol*.  
 fleistolol and, 368-369  
 gastrointestinal effects of, 71  
 geriatric usage of, issues relating to, 49  
 hematologic reactions to, 71  
 historical background of, 37  
 hypoglycemic/hyperglycemic effects of, 69-71  
 indications for use of, 50-67  
   alcohol withdrawal and, 39, 50  
   aneurysm and, 63  
   angina pectoris and, 38, 50, 54-56, 63, 188-190  
   arrhythmia and, 50, 56-59, 68  
   cardiomyopathy and, 60-63  
   congestive heart failure and, 39, 67-68  
   glaucoma and, 50, 66  
   hypertension and, 39, 50-54  
   migraine prophylaxis and, 50, 65-66  
   mitral valve prolapse and, 63  
   myocardial infarction and, 38, 50, 60  
   myocardial ischemia and, 188-189, 236-237  
 Q-T interval prolongation syndrome and, 63  
 Tetralogy of Fallot and, 63  
 thyrotoxicosis and, 39, 50, 64-65  
 tremor control and, 50, 67  
 inotropic effects of, negative, 51  
 membrane-stabilizing activity of, 43, 53  
 noncardiovascular effects of, 50, 64-67  
 oculomucocutaneous syndrome from, 72  
 overdose of, 68  
 pharmacokinetic properties of, 45-48  
 pharmacologic differences among, 39-48  
 plasma volume effects of, 53  
 potency of, 40  
 propranolol as. See *Propranolol*.  
 quinidine effect of, 53, 56  
 receptors for, 37-39  
 renin activity in relation to, 51-53  
 selection of, factors in, 72-73  
 selectivity of, 43-44  
 sinus node dysfunction from, 68  
 structure-activity relationships of, 40-42  
 sympathomimetic activity of, 44-45  
 vascular effects of, 69  
 venous tone effects of, 53  
 ventilatory effects of, 69  
 withdrawal reactions of, 38, 68  
 Betaxolol, 66  
 Bevantolol, 40  
 Biguanides, 1330-1331  
 Bisoprolol, 40  
 Blastomycosis, drug therapy for, 654  
 Blood glucose, decreased levels of. See *Hypoglycemia*.  
   glycosylated hemoglobin measurements of, 1361, 1369, 1573  
   increased levels of. See *Hyperglycemia*.  
   self-monitoring of, 1362, 1368-1369, 1573  
 Blood pressure, decreased. See *Hypotension*.  
   increased. See *Hypertension*.  
   physiologic determinants of, 529-533  
 Bone marrow examination, 1159-1160  
 Bone marrow transplantation, 1068-1069  
 Bronchiolitis obliterans, 1235  
 Bupropion, 822  
 Buspirone, alcoholism and, 879  
   anxiety disorders and, 827, 900-901  
   benzodiazepines vs, 796-797  
   panic disorder and, 805  
   pharmacology of, 795-796  
 Calcitonin, 1192-1193  
 Calcium channel blockers, 83-115, 387-388, 449-499  
   absorption of, 84-85  
   advantages and disadvantages of, 489  
   adverse effects of, 105-106, 489  
   amlodipine and, 489  
   antiplatelet activity of, 134-135  
   bioavailability of, 84-85  
   cellular action of, 83-84  
   diltiazem and. See *Diltiazem*.  
   dosages for, 87-88  
   drug interactions of, 485  
   electrophysiologic effects of, 88-89  
   excretion of, 87  
   experimental studies of, 455-456  
   half-life of, 85-87  
   hemodynamic effects of, 89-90  
   hypertension drug therapy and, 387-388  
   indications for, 489  
   angina pectoris and. See *Angina pectoris, calcium channel blockers for*.  
   arrhythmia and, 99-101  
   asthma and, 102-103  
   cerebral arterial spasm and, 104-105  
   congestive heart failure and, 96-98  
   esophageal spasm and, 104  
   hypertension and, 94-96  
   hypertrophic cardiomyopathy and, 98-99  
   migraine and, 105  
   myocardial infarction and, 93-94  
   myocardial ischemia and, 236-237  
   myometrial hyperactivity and, 104  
   pulmonary hypertension and, 101-102  
   Raynaud's phenomenon and, 103-104, 261-262  
   mechanism of action of, 88-90, 450-452, 454  
   metabolism of, 87  
   nicardipine and, 481-485  
   nifedipine and. See *Nifedipine*.

- Calcium channel blockers (*Continued*)  
  nitrendipine and, 476-481  
  nivadipine and, 489  
  overdosage of, 485  
  pharmacokinetic properties of, 84-8, 485, 489  
  rational for use of, 452-456  
  structure of, 449-450  
  vasodilator action of, 452  
  verapamil and. *See Verapamil.*
- Cancer, adrenal gland, 1124  
  fever of, 1251, 1253  
  metastatic. *See Metastatic cancer.*  
  pancreatic. *See Pancreatic cancer.*  
  thyroid. *See Thyroid carcinoma.*
- Candidiasis, 1079  
  chronic mucocutaneous, 641  
  dermatologic, 639-640  
  drug therapy for, 639-643, 657-658  
  esophagitis, 640-641  
  gastrointestinal, 640-642  
  oral, 640  
  peritonitis, 641-642  
  renal, 643  
  urinary tract, 642  
  vaginitis, 642  
  vulvar, 642
- Captopril, adverse effects of, 410-412  
  comparative analysis of, 413-414  
  dose recommendations for, 414-415  
  drug interactions of, 413  
  hemodynamic effects of, 402-403  
  historical background of, 399-400  
  hormonal effects of, 404  
  indications for, congestive heart failure and, 408-410, 415  
  hypertension drug therapy and, 388-390, 406-408, 414-415  
  pharmacokinetics of, 404-406  
  structure of, 400-401
- Cardiomyopathy, dilated, beta-adrenergic blocker drug therapy for, 62-63  
  hypertrophic, beta-adrenergic blocker drug therapy for, 60-62  
  calcium channel blockers for, 98-99  
  sudden death from, 1025
- Cardiovascular drugs, adrenergic blockers and. *See Adrenergic blockers.*  
  amiodarone and. *See Amiodarone.*  
  angiotensin-converting enzyme inhibitors and. *See Angiotensin-converting enzyme inhibitors.*  
  antianginal drugs and. *See Antianginal drugs.*  
  antiarrhythmic drugs and. *See Antiarrhythmic drugs.*  
  antihypertensive drugs and. *See Antihypertensive drugs.*  
  antiplatelet drugs and. *See Antiplatelet drugs.*  
  beta-adrenergic blockers and. *See Beta-adrenergic blockers.*  
  calcium channel blockers and. *See Calcium channel blockers.*  
  coenzyme Q10 and. *See Coenzyme Q10.*  
  ketanserin and. *See Ketanserin.*  
  nitrates and. *See Nitrates.*  
  oxygen-derived free radical damage to myocardium and, 233-238  
  allopurinol for, 233-234  
  antineutrophilic agents for, 236-237  
  antioxidants for, 234-236  
  arachidonic acid metabolism inhibitors for, 236  
  free radical scavengers for, 234-236  
  terazosin and. *See Terazosin.*  
  thrombolytic. *See Thrombolytic therapy.*  
  vasodilator. *See Vasodilator drugs.*
- Carteolol, 40
- Celiprolol, 40
- Central nervous system, beta-adrenergic blocker effect on, 51, 71
- Cerebral artery spasm, calcium channel blockers for, 104-105
- Childhood anxiety disorders, 757-758
- Childhood depression, 831-845  
  adjustment disorder with, 836-837, 839  
  bipolar disorder, 834-835  
  case reports of, 837-839  
  clinical features of, 833-841  
  comorbidity of, 837  
  cyclothymia, 835  
  despair and, 831  
  detachment and, 831  
  dysthymia, 836  
    major depression and, 837-838  
    overanxious disorder and, 838-839  
  epidemiology of, 832-833  
  historical background of, 831-832  
  major, 835-838  
  origins of, 839-840  
  protest and, 831  
  suicidal behavior and, 841  
  symptoms of, 834  
  treatment of, 841-843  
    drug therapy, 841-842  
    psychosocial, 842-843
- Childhood diabetes. *See Diabetes mellitus, childhood.*
- Chloroquine, 684
- Cholangitis, fever of, 1251  
  geriatric patient, 1216
- Cholecystitis, geriatric patient, 1216
- Cholestyramine, 1391
- Churg-Strauss syndrome, 1234
- Cibenzoline, 276-282  
  antiarrhythmic effects of, 277  
  dosages for, 277, 278, 282  
  drug interactions of, 277  
  electrophysiologic action of, 276-277, 280



- hemodynamic effects of, 277, 280
- indications for, 277, 280, 282
- metabolism of, 277, 278
- pharmacokinetics of, 277, 278
- side effects of, 277, 280
- Ciclopirox olamine, 638
- Cifenline. *See Cibenzone.*
- Cilastin, 568
  - chemistry of, 568, 569
  - imipenem administration with, 573-575
- Ciprofloxacin, adverse effects of, 629-630
  - chemistry of, 623
  - indications for, 630-632
    - cystic fibrosis and, 632
    - diarrhea and, 632
    - osteomyelitis and, 633
    - respiratory infections and, 632
    - sexually transmitted diseases and, 631
    - skin infections and, 633
    - urinary tract infections and, 630, 631
  - pharmacology of, 627-629
  - prophylactic use of, 633-634
  - resistance to, 625
  - spectrum of activity of, 625-627
- Cirrhosis of liver, nitrate drug therapy for, 24
- Clofibrate, 136, 1392
- Clonidine, 390
- Clotting mechanism, 120-124
- Cocaine abuse, anxiety disorder associated with, 877
  - depression associated with, 874-875, 879
  - mood changes from, 871-872
- Coccidioidomycosis, drug therapy for, 655-656
- Coenzyme Q10, 243-258
  - adverse effects of, 252-253
  - antioxidant activity of, 243
  - biologic actions of, 244
  - chemistry of, 244
  - historical background of, 243-244
  - indications for use of, adriamycin cardio-toxicity and, 250
    - angina pectoris and, 246-248
    - arrhythmia and, 252
    - congestive heart failure and, 248-249
    - hypertension and, 249-250
    - mitral valve prolapse and, 252
    - muscular dystrophy and, 252
    - myocardial ischemia and, 243-258
  - membrane stabilizing effect of, 243
  - pharmacokinetic properties of, 245-246
  - therapeutic action of, 245
- Colestipol, 1391-1392
- Collagen vascular disease, fever of, 1253-1254
  - mesenteric ischemia and, 1111
- Colonic volvulus, geriatric patient 1220
- Congestive heart failure, 1235
  - alpha-adrenergic blockers for, 431-432
  - angiotensin-converting enzyme inhibitors for, 408-410, 415
  - beta-adrenergic blockers and, 39, 67-68
  - calcium channel blockers for, 96-98
  - coenzyme Q10 for, 248-249
  - nitrate drug therapy for, 5, 21-24, 26, 29, 30
  - terazosin for, 444
- Connective tissue disease, fever of, 1253-1254
  - pulmonary, 1234-1235
- Coronary artery bypass surgery, reperfusion of ischemic myocardium through, 200, 217-218
- Coronary artery disease, silent myocardial ischemia and. *See Silent myocardial ischemia, coronary artery disease and sudden death from, 1015-1016*
- Crohn's disease, 1255
- Cryoglobulinemia, 1159-1160
- Cryptococcosis, drug therapy for, 656-657
- Cyclandelate, 259
- Cycloserine, 664
- Cyclothymia, childhood, 835
  - cocaine abuse and, 874
- Cystic fibrosis, 1235-1236
- Cysts, thyroid. *See Thyroid gland, cysts of.*
- Cytomegalovirus, 1079-1081, 1252
- Dazoxiben, 153
- DDC therapy, 709
- Depression, 745-746
  - adjustment disorder with, 745
  - alcoholism and, 872-874
  - benzodiazepine abuse and, 875
  - biologic basis for, 765-780
    - combination theories/interactions and, 776-778
    - genetic factors and, 778-780
    - neuroendocrine studies of, 772-775
    - neurotransmitter studies of, 765-772
    - sleep studies of, 775-776
  - bipolar disorder and, 746
  - alcohol abuse and, 872-873
  - childhood, 834-835
  - cocaine abuse and, 875
  - childhood. *See Childhood depression.*
  - cocaine abuse and, 874-875
  - cost considerations of, 747
  - diagnosis of, 747-749, 753-757
  - Beck Depression Inventory for, 916
  - Center for Epidemiological Studies-Depression Scale for, 916
  - childhood disorders and, 833-841
  - geriatric disorders and, 851-852
  - Hamilton Rating Scale for Depression for, 916

## Depression (Continued)

diagnosis of, Inventory to Diagnose

Depression for, 916

MMPI for, 911-912, 915-916

psychological tests for, 911-913, 915-916

Rorschach test for, 912

TAT for, 913

Zung Self-rating Depression scale for, 916

drug-resistant, 987-909

alcohol abuse and, 905

dosage and, 905-906

duration of depressive episode and, 902

duration of therapy and, 905-906

medical illness and, 903, 904

patient compliance to regimens and, 905

personality traits associated with, 902

physician's attitude to, 906

prediction of, 902-904

reasons for, 903-906

drug therapy, 815-823, 841, 923-924

amoxapine and, 820

bupropion and, 822

childhood disorders and, 841-842

fluoxetine and, 821-822

maprotiline and, 820

monoamine oxidase inhibitors and, 822-823

trazodone and, 821

tricyclic antidepressants and, 816-820, 841-842

dysthymia and. See *Dysthymia*.

epidemiology of, 747

childhood disorders and, 832-833

geriatric disorders and, 847-848

genetics of, 778-780

geriatric. See *Geriatric patients, depression of*.

major, 746

childhood, 835-836

cocaine abuse and, 874-875

epidemiology of, 868

opiate abuse and, 875

manic, 746

neuroendocrine studies of, 772-775

growth hormone, 774

hypothalamic-pituitary-adrenal axis and, 772-773

hypothalamic-pituitary-thyroid axis and, 774

neurotransmitter interactions in, 776-778

prolactin and, 774-775

sleep disturbances and, 776-778

neurotic, 745

neurotransmitter hypothesis of, 765-772

biological markers supporting, 770-772

catecholamine, 766-767

cholinergic factors in, 770

dopamine, 766-768

dysregulated, 769-770

hormonal fluctuations and, 776-778

indoleamine, 768, 771-772

monoamine receptors in, 768-769

monoamine synthesis and breakdown in, 766-767

platelet MAO activity and, 772

sleep disturbances and, 776-778

urinary MHPG activity and, 770-771

opiate abuse and, 875

patient and family education on, 887-896

final phase of hospitalization and, 893-894

initial phase of hospitalization and, 890-891

middle phase of hospitalization and, 891-893

postdischarge treatment and, 894

review of literature on, 888-890

psychiatric consultation for, 929-934

liaison services for, 933-934

process of, 930-931

reasons for, 931-933

referral vs, 929-930

psychological assessment of, 911-913, 915-916

psychotherapy for, 918-920, 922-924

behavioral theory for, 920

childhood disorders and, 842-843

cognitive theories for, 918-919

combination drug therapy with, 923-924

drug therapy vs, 923

effectiveness of, 922-924

Rehm's self-control theory for, 919

sedative abuse and, 875

sleep studies of, 775-778

substance abuse and, 867, 869, 872-875, 878-880

suicidal behavior and, 944-945

treatment of, barriers to, 748-749

childhood disorders and, 841-843

drug therapy, 815-823, 841, 923-924

goals of, 749-750

psychotherapy, 918-920, 922-924

referral for, 748

substance abuse and, 878-880

types of, 745-746

DHPG, 702-703

adverse effects of, 702

dosages for, 703

indications for, 702-703

mechanism of action of, 702

pharmacokinetics of, 702

spectrum of activity of, 702

toxicity of, 702

Diabetes mellitus

adolescent, 1566, 1574-1575

- atherosclerosis and, 1379-1380  
lipid type and content correlated to, 1380-1381  
National Cholesterol Education Program recommendations regarding, 1388-1390  
noninsulin-dependent diabetes mellitus and, 1360  
treatment of, 1386-1390
- childhood, **1565-1576**  
classification of, 1566  
diagnosis of, 1565-1566  
dietary therapy for, 1572-1573  
glycosylated hemoglobin monitoring in, 1573-1574  
home glucose monitoring in, 1573  
insulin therapy for, 1571-1572  
ketoacidosis of, 1567-1570  
outpatient management of, 1571  
physical examination for, 1574-1575  
treatment of, 1566-1575
- coronary artery disease and, 1379-1380  
dietary treatment of, **1285-1299**  
ADA recommendations, 1285-1286  
childhood diabetes and, 1572-1573  
exercise and, 1315-1316  
fiber considerations in, 1295-1296  
fructose consumption considerations in, 1294  
glycemic index of foods in, 1290-1291  
hypotension and, 1408  
insulin-dependent diabetes and, 1286-1288, 1374  
lipid disorders and, 1390-1391  
nephropathy and, 1480-1484  
non-nutritive sweeteners in, 1294-1295  
noninsulin-dependent diabetes and, 1288-1290, 1358  
nutritive sweeteners in, 1294  
pregnancy and, 1502, 1505  
sucrose consumption considerations in, 1291-1294
- exercise and, **1301-1321**  
benefits of, 1302  
caloric restriction and, effect of, 1315-1316  
diet prior to, effect of, 1305-1306  
duration of, effect of, 1305  
hypoglycemia as complication of, 1310, 1314-1315  
insulin-dependent diabetes, effect on, 1307-1313, 1375  
intensity of, effect of, 1304-1305  
ketosis as complication of, 1310  
level of physical training and, effect of, 1305  
metabolic adjustments after, 1306-1307, 1310  
metabolic adjustments during, 1303-1304, 1308-1309, 1314-1315  
noninsulin-dependent diabetes, effect on, 1303-1315  
prevention of complications of, 1310-1315  
risks of, 1302-1303  
foot disorders of. *See Diabetic foot disorders.*  
hyperosmolar hyperglycemic nonketotic coma and, **1545-1563**  
complications of therapy for, 1558-1560  
definition of, 1548  
diagnosis of, 1550-1552  
laboratory tests of, 1550-1552  
pathophysiology of, 1548-1549  
treatment of, 1554-1558
- hypertension and, **1399-1415**  
baroreceptor sensitivity in, 1404-1405  
blood pressure regulating systems in, 1404  
calcium metabolism in, 1405-1406  
cardiovascular risks of, 1400-1402  
catecholamines in, role of, 1404  
clinical evaluation of, 1407  
dietary therapy for, 1408  
drug therapy for, 1408-1410  
epidemiology of, 1399-1400  
expansion of extracellular fluid volume in, 1402-1403  
hyperinsulinemia in, 1406-1407  
insulin resistance in, 1405-1407  
nephropathy associated with, 1476, 1478-1481, 1483  
pathophysiology of, 1402-1407  
peripheral vascular resistance in, 1402-1403  
prostaglandins in, role of, 1404  
retinopathy correlation to, 1426  
sodium retention in, 1403-1404  
treatment of, 1407-1410
- hypoglycemia and, drug therapy and. *See Oral hypoglycemic agents.*  
exercise-induced, 1310, 1314-1315  
neonatal, 1497-1498
- insulin-dependent, **1365-1378**  
atherosclerosis and, 1379-1380  
average therapy for, 1366, 1370-1372, 1374  
dietary therapy for, 1286-1288, 1374  
exercise and, 1375  
goals of therapy of, 1365-1366  
insulin therapy for, 1370-1374  
intensive therapy for, 1366-1367, 1372-1374  
levels of therapy of, 1366-1368  
lipid disorders and, 1383-1384  
minimal therapy for, 1366, 1370, 1374  
nephropathy and, 1466-1487  
physician monitoring of blood glucose levels of, 1369  
self-monitoring of blood glucose levels of, 1368-1369

**Diabetes mellitus (Continued)**

- insulin therapy for. See *Insulin therapy*.
- ketoacidosis and, 1545-1563
  - bicarbonate therapy for, 1553-1554
  - catecholamines in, role of, 1546
  - childhood diabetes and, 1567-1570
  - complications of therapy for, 1558-1560
  - diagnosis of, 1550-1552
  - exercise-induced, 1310
  - fluid therapy for, 1554
  - follow up care for, 1557-1558
  - hormones in, role of, 1545-1546
  - insulin therapy and, 1552-1553
  - laboratory tests of, 1550-1552
  - pathophysiology of, 1545-1548
  - phosphate replacement therapy for, 1553
  - recommended therapy for, 1554-1557
  - treatment of, 1552-1558
  - water and electrolyte disturbances of, 1547-1548
- lipid disorders and, 1379-1398
  - chylomicronemia syndrome and, 1386
  - dietary therapy for, 1390-1391
  - drug therapy for, 1391-1393
  - insulin-dependent diabetes mellitus and, 1383-1384
  - National Cholesterol Education Program recommendations regarding, 1388-1390
  - noninsulin-dependent diabetes mellitus and, 1360-1361, 1384-1386
  - treatment of, 1386-1393
- metabolic control in relation to vascular complications, 1271-1284
  - animal studies of, 1272-1275
  - human studies of, 1275-1281
- neonatal effects of, 1495-1498
  - bilirubin metabolism and, 1498-1499
  - calcium metabolism and, 1498
  - congenital malformations from, 1495-1497
  - hypoglycemia and, 1497-1498
  - macrosomia and, 1497
  - magnesium metabolism and, 1498
  - polycythemia and, 1498-1499
  - respiratory distress syndrome and, 1498
  - shoulder dystocia and, 1497
  - traumatic birth injury and, 1497
- nephropathy of. See *Diabetic nephropathy*.
- neuropathy of. See *Diabetic neuropathy*.
- noninsulin-dependent, 1355-1364
  - atherosclerosis and, 1379-1380
  - complications of, 1360-1361
  - continuing care for, 1361-1362
  - dietary therapy for, 1288-1290, 1358
  - frequency of office visits for, 1361-1362
  - goals of therapy for, 1356-1357
  - initial evaluation of, 1355-1356
  - insulin therapy for, 1359-1360, 1363
  - laboratory tests of, 1356
  - lipid disorders and, 1384-1386
  - medical history of, 1355-1356
  - modification of therapy for, 1362
  - monitoring of therapy for, 1362
  - nephropathy and, 1466, 1488
  - oral hypoglycemic agents for. See *Oral hypoglycemic agents*.
  - patient education for, 1360
  - physical examination of, 1355-1356
  - treatment plan for, 1357-1361
- oral hypoglycemic agents for. See *Oral hypoglycemic agents*.
- pancreatic cancer from, 981
- perinephric abscess and, 1000-1001
- pregnancy and, 1493-1511
  - classification of, 1499-1500
  - congenital malformations from, 1495-1497
  - counseling of patient during, 1505-1506
  - diagnosis of, 1500-1501
  - dietary therapy for, 1502, 1505
  - fetal death from, 1494-1495
  - fetal surveillance during, 1502-1503
  - gestational diabetes, 1505
  - insulin therapy for, 1501-1502, 1505
  - pathophysiology of, 1493-1494
  - perinatal morbidity and mortality, 1494-1499
  - retinopathy and, 1427
  - risk assessment for, 1499-1500
  - timing of delivery for, 1503-1505
  - treatment of, 1501-1506
- retinopathy of. See *Diabetic retinopathy*.
- surgical treatment of, 1531-1543
  - alternatives to, 1531-1532
  - emergency, 1540-1541
  - glucose metabolism and, 1532, 1534
  - glucose monitoring and, 1536-1537
  - ketone body formation and, 1532
  - metabolic decompensation and, 1535-1536
  - perioperative regimens and care, 1533-1538
  - postoperative care, 1541
  - principles of, 1538-1539
  - problems of, 1531
  - routine, 1539-1540
- vascular complications of, 1271
  - foot disorders and. See *Diabetic foot disorders*.
  - metabolic control and, relationship between, 1271-1284
  - nephropathy and. See *Diabetic nephropathy*.
  - retinopathy and. See *Diabetic retinopathy*.
- Diabetic foot disorders, 1513-1530
  - autonomic neuropathy and, 1516
  - classification of lesions of, 1522
  - diagnosis of, 1517-1518

- etiology of, 1513-1516
- macrovascular disease and, 1516
- microvascular disease and, 1516, 1526-1527
- osteopathy and, 1526
- pathogenesis of, 1516-1517
- physical examination for, 1517-1518
- prevention of, 1518-1521
- risk factors predisposing to, 1514-1516
- somatic neuropathy and, 1513-1516
- treatment of, 1521-1527
  - drug therapy, 1526-1527
  - grade 1 lesion, 1522-1523
  - grade 2 lesion, 1523-1524
  - grade 3 lesion, 1524
  - grade 4 lesion, 1524-1525
  - grade 5 lesion, 1525
  - grade zero foot, 1521-1522
  - specialists in, 1525-1526
  - surgical therapy, 1526
- Diabetic nephropathy, 1465-1492**
- classification of, 1469
- differential diagnosis of, 1482
- end-stage renal failure and, 1482-1485
  - antihypertensive drug therapy for, 1483
  - dietary therapy for, 1483-1484
  - fluid retention and, 1483
  - glycemic control in management of, 1483
  - hypertension and, 1483
  - renal replacement therapy for, 1484-1485
- glomerular hyperfiltration and, 1466-1467
- insulin-dependent diabetes mellitus and, 1466-1487
- metabolic control and, relationship between, 1271-1284
  - animal studies of, 1273-1275
  - human studies of, 1279-1281
- microalbuminuria and, 1467-1482
- antihypertensive drug therapy for, 1478-1481
- body fluid changes associated with, 1477
- cardiovascular changes associated with, 1476-1477
- diagnosis of, 1468-1469
- dietary therapy for, 1480-1482
- glycemic control in management of, 1477-1478
- hypertension associated with, 1476, 1478-1481
- prevalence of, 1473-1476
- renal structure and function with, 1476
- retinal changes associated with, 1426-1427, 1476-1477
- stages of, 1470-1473
- treatment of, 1477-1482
- vascular changes associated with, 1477
- noninsulin-dependent diabetes mellitus and, 1466, 1488
- treatment of, 1486-1487
- Diabetic neuropathy, 1439-1464**
- autonomic neuropathy, 1451-1457
  - cardiovascular effects of, 1455
  - counterregulatory effects of, 1457
  - diagnosis of, 1442-1444
  - foot ulceration and, 1516
  - gastrointestinal effects of, 1456
  - genitourinary effects of, 1456-1457
  - sudomotor effects of, 1457
- causes of, 1440
- classification of, 1444
- diagnosis of, 1442-1444
- electrophysiologic tests of, 1442, 1444
- normal physiologic considerations vs, 1440-1442
- pathogenesis of, 1444-1449
  - functional abnormalities in, 1445
  - metabolic abnormalities in, 1445-1448
  - structural abnormalities in, 1445
  - vascular abnormalities in, 1444-1445
- quantitative sensory tests of, 1442
- somatic neuropathy, 1449-1451
  - characteristics of, 1452-1454
  - foot ulceration and, 1513-1516
  - painful, 1451
  - painless, 1450-1451
- treatment of, 1457-1460
  - aldose reductase inhibitors in, 1459-1460
  - glycemic control in, 1458-1459
  - types of, 1441
- Diabetic retinopathy, 1415-1437**
- age correlation to, 1421
- blood pressure correlation to, 1426
- duration of diabetes in relation to onset of, 1419-1420
- epidemiology of, 1418-1422
- genetic factors of, 1422
- glycemic control correlation to, 1422-1426
- kidney disease correlation to, 1426-1427, 1476-1477
- metabolic control and, relationship between, 1271-1284, 1422-1426
  - animal studies of, 1272-1273
  - human studies of, 1276-1279, 1422-1426
- natural history of, 1415-1416
- ophthalmologic examination of, 1432-1433
- pathogenesis of, 1416-1418
- pregnancy and, 1427
- proteinuria correlation to, 1426
- risk factors predisposing to, 1418-1427
- severity of diabetes in relation to onset of, 1419-1420
- sex correlation to, 1421-1422
- smoking correlation to, 1426

- Diabetic retinopathy (*Continued*)  
treatment of, 1427-1433  
drug therapy, 1428  
glycemic control, 1427-1428  
ophthalmologic care, 1432-1433  
photocoagulation, 1428-1430  
rehabilitation therapy, 1433  
surgical therapy, 1428-1432  
vitrectomy, 1430-1432
- Diet, diabetes mellitus and. See *Diabetes mellitus, dietary treatment of.*
- Diethylcarbamazine citrate, 679
- Dieulafoy, ulcer of, 1172-1173
- Dilevalol, 44, 45
- Diltiazem, 84, 468-476  
antiplatelet activity of, 134  
dosages for, 88  
drug interactions of, 485  
electrophysiologic effects of, 89, 99-100  
hemodynamic effects of, 89-90, 468  
indications for use of, angina pectoris and, 91-93, 193, 473-474  
arrhythmia and, 100  
congestive heart failure and, 97  
hypertension and, 95-96, 387-388, 469-474  
hypertensive crisis and, 473  
myocardial infarction and, 94  
myocardial ischemia and, 193  
pulmonary hypertension and, 102  
Raynaud's phenomenon and, 103-104, 262  
mechanism of action of, 451-452  
pharmacokinetic properties of, 84-87  
structure of, 449-450  
sustained-release, 469-473  
therapeutic effects of, 469-474  
animal studies of, 455  
clinical studies of, 469
- Dipyridamole, antiplatelet activity of, 131, 170  
indications for use of, angina pectoris and, 152  
aortocoronary bypass graft patency maintenance and, 158-165  
coronary angioplasty restenosis prevention and, 166, 167  
myocardial infarction prevention and, 139-148
- Diuretics, 381-384  
hypertension drug therapy and, 381-384  
loop, 384  
potassium-sparing, 383-384  
thiazide-type, 381-383
- Diverticulitis, geriatric patient 1218-1219
- Drug abuse, anxiety disorders associated with, 877, 879-880  
comorbidity of, 869  
depression associated with, 874-875, 879-880  
epidemiology of, 868  
mood changes from, 871-872  
psychopathology associated with, 870-871  
suicidal behavior and, 945  
treatment of, 879-880
- Drugs, cardiovascular. See *Cardiovascular drugs.*
- Dysthymia, 745-746  
childhood, 836-839  
major depression and, 837-838  
overanxious disorders and, 838-839  
cocaine abuse and, 874  
epidemiology of, 868
- Electroconvulsive therapy, 828, 858
- Emetine, 677
- Enalapril, adverse effects of, 410-412  
dosage recommendations for, 414-415  
drug interactions of, 413  
hemodynamic effects of, 402-403  
indications for, congestive heart failure and, 408-410, 415  
hypertension and, 388-390, 406-408, 414  
pharmacokinetics of, 405-406  
structure of, 400-401
- Encainide, 288-291  
antiarrhythmic effects of, 290  
dosages for, 278, 291  
drug interactions of, 291  
electrophysiologic action of, 280, 289  
indications for, 280, 291  
metabolism of, 278, 289-290  
pharmacokinetics of, 278, 289-290  
side effects of, 280, 290-291
- Endocarditis, subacute bacterial, 1252
- Enoxacin, chemistry of, 623  
pharmacology of, 627-629  
resistance to, 625  
spectrum of activity of, 625-627
- Eosinophilic granuloma, 1238-1239
- Esmolol, 40, 298-301, 360-368  
dosages for, 279, 300-301, 367-368  
drug interactions of, 300, 367  
electrophysiologic actions of, 281, 299, 362-363  
hemodynamic effects of, 281, 299-300, 362  
indications for, 281, 300-301, 363-366  
arrhythmia and, 300, 363-364  
hypertension and, 365-366  
myocardial ischemia and, 364-365  
tachyarrhythmias and, 363-364  
metabolism of, 279, 299, 360-361  
pharmacodynamics of, 361-363  
pharmacokinetic properties of, 46, 48, 279, 299, 360-361  
potency of, 40

- side effects of, 281, 300, 366-367
- structure of, 360
- Esophageal disease, calcium channel blockers for, 104
- nitrate drug therapy for, 24
- Ethambutol, 664
- Ethionamide, 664
- Ethmozin, 278, 280, 286-288
  - antiarrhythmic effects of, 287-288
  - dosages for, 278, 288
  - drug interactions of, 288
  - electrophysiologic action of, 280, 286-287
  - hemodynamic effects of, 280, 287
  - indications for, 280, 288
  - metabolism of, 278, 287
  - pharmacokinetics of, 278, 287
  - side effects of, 280, 288
- Exercise, diabetes mellitus and. See *Diabetes mellitus, exercise and.*
- Eye infections, antimicrobial/antibiotic therapy for, 717-722
  - administration of, routes of, 719-720
  - bacteriology and, 718-719
  - pharmacokinetics of, 717-718
  - recommendations for, 720-721
- Fever, abscess, 1251-1252
  - allergic vasculitis, 1254
  - cholangitis, 1251
  - colitis, 1255
  - drug-induced, 1249
  - endocarditis, subacute bacterial, 1252
  - essential hyperthermia, 1248
  - factitious, 1249
  - giant cell arteritis, 1254
  - hematoma, 1255
  - infectious causes of, 1250-1251
  - liver disease, 1251, 1255
  - lupus erythematosus, 1254
  - malignancy causing, 1251, 1253
  - metabolic disorders causing, 1250
  - occupational causes of, 1249-1250
  - of unknown origin, 1247-1261
    - biopsy for, diagnostic, 1257
    - classification of, 1247-1248
    - computerized tomography for, 1257-1258
    - diagnostic tests for, 1256-1259
    - drug therapy for, 1258-1259
    - etiology of, 1247-1255
    - exploratory laparotomy for, 1258
    - historical background of, 1247
    - laboratory tests for, 1256-1257
    - medical history of, 1256
    - physical examination for, 1256
    - radionuclide imaging for, 1257-1258
    - ultrasonography for, 1257-1258
- polymer fume, 1249
- polymyalgia rheumatica, 1254
- psychogenic, 1248
- pulmonary emboli, 1255
- rheumatic, 1252-1253
- rheumatoid arthritis, 1254
- temporal arteritis, 1254
- thyroiditis, 1255
- tuberculosis, 1252
- typhoid, 1253
- viral infection, 1252
- Flecainide, 291-293
  - antiarrhythmic effects of, 292
  - dosages for, 278, 293
  - drug interactions of, 292-293
  - electrophysiologic action of, 280, 291
  - hemodynamic effects of, 280, 292
  - indications for, 280, 293
  - metabolism of, 278, 291-292
  - pharmacokinetics of, 278, 291-292
  - side effects of, 280, 292
- Fleistolol, 368-369
- Flucytosine, 648-650
- Fluoxetine, 821-822
- Foot disorders, diabetes mellitus and. See *Diabetic foot disorders.*
- Fungal infections, drug therapy for. See *Antifungal agents.*
- in vitro susceptibility testing of, 644
- types of, 637
- Furazolidine, 677-678
- Gallopamil, 84
- Gallstones, geriatric patient, 1216
- Gastric volvulus, geriatric patient 1217-1218
- Gastrointestinal bleeding, 1169-1176
  - angiodysplasia and, 1171-1172
  - arteriography of, 1174, 1176
  - arteriovenous malformations and, 1172
  - diagnostic tests for, 1173-1176
  - exploratory laparotomy of, 1174, 1176
  - fistulas and, arterial-enteric, 1170-1171
  - radionuclide scans of, 1173-1174, 1176
  - small bowel lesions and, 1170
  - ulcer of Dieulafoy and, 1172-1173
  - vascular anomalies and, 1171-1173
  - vascular ectasias and, 1171, 1172
  - x-ray examination of, 1173, 1176
- Gemfibrozil, 1392-1393
- Generalized anxiety disorder, 746
  - biologic basis for, 791-797
    - agonists/antagonists of benzodiazepine and, 793-794
    - benzodiazepine/buspirone comparative analysis and, 796-797
    - buspirone and, 795-797
    - GABA-benzodiazepine receptor complex and, 792-797

- Generalized anxiety disorder (*Continued*)  
 clinical features of, 791-792  
 diagnosis of, 761-762  
 epidemiology of, 792  
 opiate abuse and, 877  
 treatment of, 879, 901
- Gentamicin, 601
- Geriatric patients, abdominal aortic aneurysm of, 1220-1221
- abdominal disease of, 1213-1224
- appendicitis of, 1218
- biliary disorders of, 1216
- bladder perforation of, 1221
- cholecystitis of, 1216
- colonic volvulus of, 1220
- depression of, 847-866
- biologic basis for, 849-850
- clinical course of, 859-860
- dexamethasone test of, 851-852
- diagnosis of, 851-852
- drug therapy for, 853-859
- lithium carbonate and, 858-859
- monoamine oxidase inhibitors and, 855-857
- psychostimulants and, 857
- tricyclic antidepressants and, 853-856
- epidemiology of, 847-848
- masked, 850-851
- pathogenesis of, 848-850
- phenomenology of, 850
- pseudodementia and, 850
- suicidal behavior and, 860
- treatment of, 852-859
- drug therapy, 853-859
- efficacy of, 853
- electroconvulsive therapy for, 858
- principles of, 852-853
- diverticulitis of, 1218-1219
- gallstones of, 1216
- gastric volvulus of, 1217-1218
- hernias of, 1215, 1219
- intestinal obstruction of, 1215, 1219-1220
- mesenteric ischemia of, 1214-1215
- pancreatic disorders of, 1216
- peptic ulcer disease of, 1216-1217
- urinary tract infections of, 1221
- Giant cell arteritis, 1254
- Glaucoma, beta-adrenergic blocker drug therapy for, 50, 66
- Glucose, blood. See *Blood glucose*.
- Growth hormone, depression and, 774
- Guanabenz, 390
- Guanadrel, 390-391
- Guanethidine, 262, 390-391
- Haloprogyn, 637-638
- Heart disease, angina pectoris. See *Angina pectoris*.
- atherosclerosis and. See *Atherosclerosis*.
- cardiomyopathy. See *Cardiomyopathy*.
- congestive heart failure and. See *Congestive heart failure*.
- coronary artery disease. See *Coronary artery disease*.
- drug therapy for. See *Cardiovascular drugs*.
- hypertension and. See *Hypertension*.
- myocardial infarction. See *Myocardial infarction*.
- myocardial ischemia. See *Myocardial ischemia*.
- sudden death. See *Sudden cardiac death*.
- Heart surgery, aortocoronary bypass. See *Aortocoronary bypass surgery*.
- coronary artery bypass. See *Coronary artery bypass surgery*.
- percutaneous transluminal coronary angioplasty. See *Percutaneous transluminal coronary angioplasty*.
- reperfusion of ischemic myocardium through, 200-201
- transplantation, 1070
- Hemostasis, 117-118, 202-203
- Hematomas, 1255
- Heparin, thromboembolic disease drug therapy with, 262-264
- Hepatitis, 1251
- Hernias, geriatric patient, 1215, 1219
- Herpes virus, acyclovir drug therapy for, 691-692, 695-697
- pneumonia from, 1081
- Histoplasmosis, drug therapy for, 655
- Hodgkin's disease, 1068, 1236
- HPA-23, 707-708
- Hybridons, 708
- Hydralazine, 391
- Hyperaldosteronism, 1117-1131
- adenomas causing, 1117
- biochemical markers for, 1124-1126
- computerized tomography of, 1126
- differential diagnosis of, 1124-1126
- scintigraphic localization of, 1126-1127
- venous hormone sampling for localization of, 1127
- adrenal gland carcinoma causing, 1124
- adrenal hyperplasia causing, 1123-1124
- biochemical markers for, 1124-1126
- computerized tomography of, 1126
- differential diagnosis of, 1124-1126
- scintigraphic localization of, 1126-1127
- biochemical markers of, 1123-1124
- diagnosis of, 1117-1128
- captopril test for, 1122
- computerized tomography for, 1124, 1126
- 18-hydroxycorticosterone analysis for, 1124-1125
- magnetic resonance imaging for, 1126
- preliminary, 1118-1120
- saline infusion test for, 1121-1122



- scintigraphy for, 1126-1127
- screening tests for, 1118-1120
- sodium loading test for, 1121
- suppression tests for, 1122-1123
- ultrasonography for, 1126
- venous hormone sampling for, 1123-1124, 1127-1128
- dopamine in, role of, 1124-1125
- endocrine disorders associated with, 1118
- endorphins in, role of, 1124
- familial glucocorticoid suppressible, 1124, 1126
- idiopathic, 1117
  - diagnosis of, 1123
  - unilateral hyperplasia, 1123
- pituitary-derived stimulating factor causing, 1124
- prevalence of, 1117
- screening tests for, 1117-1120
  - aldosterone measurements, 1120
  - plasma renin activity, 1119-1120
  - serum potassium, 1118-1119
- signs and symptoms of, 1118
- types of, 1123-1126
- Hyperglycemia, beta-adrenergic blocker-induced, 69-71**
  - diabetes mellitus and. See *Diabetes mellitus*.
- Hypertension, alcoholism and, 1145**
  - aldosterone and. See *Hyperaldosteronism*.
  - beta-adrenergic blocker drug therapy for, 39, 50-54
    - calcium channel blockers for, 94-96
    - cardiovascular mortality and, 374-377
    - childhood, 407-408
    - coenzyme Q10 for, 249-250
    - definition of, 524
    - diabetes mellitus and. See *Diabetes mellitus, hypertension and*.
    - drug therapy for. See *Antihypertensive drugs*.
  - elderly patients with, 391-392, 523-547
    - epidemiology of, 524-529
    - drug therapy for, 541-544
  - epidemiology of, 374-377
  - hypercalcemic, 452-454
  - portal, 24
  - pulmonary. See *Pulmonary hypertension*.
  - risk factors for, 534-537
  - treatment of, aggressive, rationale for, 374-380
    - alcohol restriction and, 380
    - Austrian Trial study and, 378
    - clinic studies of, 377-380
    - dietary, 380, 381
    - drug therapy. See *Antihypertensive drugs*.
    - exercise, 380-381
  - Hypertension Detection and Follow-up Program study of, 379
- Multiple Risk Factor Intervention Trial**
  - study of, 379-380
  - nonpharmacologic, 373-374, 380-381
  - Oslo study of, 378
  - Veterans Administration Trial study of, 378
  - weight reduction, 380
- Hypoglycemia, beta-adrenergic blocker-induced, 69-71**
  - diabetes mellitus and. See *Diabetes mellitus, hypoglycemia and*.
  - neonatal, 1497-1498
- Hypoglycemic agents, oral. See Oral hypoglycemic agents.**
- Hypotension, drug therapy-induced, angiotensin-converting enzyme inhibitor, 412-413**
  - esmolol, 366
  - prazosin, 436
- Ibuprofen, 128
- Iloprost, 153
- Imidazole, 130
- Imipenem, 567-579**
  - adverse effects of, 574-575
  - chemistry of, 567-568
  - dosages for, 573-574
  - indications for, 575-577
  - mechanism of action of, 572
  - pharmacokinetics of, 572-573
  - spectrum of activity of, 568-572
- Immune system, beta-adrenergic blocker effect on, 72**
- Immunocompromised patients, lung infections of. See Lung infections, immunocompromised patients with.**
- Immunomodulator therapy, 709**
- Indomethacin, 128, 167
- Indoramin, indications for, congestive heart failure and, 432**
  - hypertension and, 431
- Insulin therapy, 1337-1354**
  - absorption of insulin in, 1345-1347
  - allergies to, 1338
  - applicability of, 1349
  - average, 1370-1372
  - beef insulin for, 1341
  - childhood diabetes, 1571-1572
  - concentration considerations for, 1343
  - human insulin for, 1341-1343
  - injection technique for, 1343-1345
  - intensive, 1372-1374
  - intermediate acting insulin for, 1348-1349
  - minimal, 1370
  - noninsulin-dependent diabetes mellitus and, 1359-1360, 1363
  - pork insulin for, 1341

- Insulin therapy (*Continued*)  
 pregnancy considerations for, 1501-1502, 1505  
 preparations of insulin for, 1347-1349  
 prolongation of action of, 1340-1341, 1349  
 purification of insulin extracts for, 1337-1340  
 rapid-onset insulin for, 1348  
 sheep insulin for, 1341  
 species of origin of insulin for, 1341-1343  
 stability and miscibility of insulin for, 1343-1345
- Interferons, 709-711  
 adverse reactions to, 710  
 classification of, 709  
 indications for, 710-711  
 mechanism of action of, 709  
 pharmacokinetics of, 709-710  
 toxicity of, 710
- Intermittent claudication, vasodilator drug therapy for, 259-261
- Intestinal obstruction, geriatric patient, 1215, 1219-1220
- Iodoquinol, 675
- Ischemia, mesenteric. *See Mesenteric ischemia.*  
 myocardial, silent. *See Silent myocardial ischemia.*
- Isoniazid, 662-663
- Isosorbide dinitrate, formulations of, 24, 26  
 indications for use of, angina pectoris and, 15, 17-18, 186-187  
 congestive heart failure and, 21-23  
 myocardial ischemia and, 186-187  
 tolerance to, 30
- 5-Isosorbide mononitrate, 3, 26, 30
- Isoxsuprine, 259
- Ivermectin, 680-681
- Kanamycin, 601
- Kearns-Sayre syndrome, 252
- Ketanserin, 136, 501-522  
 antiplatelet effects of, 509  
 blood viscosity effects of, 509  
 catecholamine release and, 511  
 dosage regimens for, 517-518  
 hemodynamic effects of, 508-509  
 hemorrhologic effects of, 509  
 hyperaldosteronism drug therapy and, 517  
 hypertension drug therapy and, 511-519  
 clinical studies of, 511-513  
 combination therapy and, 516  
 comparative studies of, 513-516  
 intravenous studies of, 512  
 long term therapy and, 517  
 placebo-controlled oral studies of, 512-513
- mechanisms of action of, 505-507  
 alpha-adrenergic blockade and, 506-507  
 serotonin receptor blockade and, 505-506  
 metabolic actions of, 509-511  
 pharmacokinetics of, 511  
 side effects of, 518-519  
 sodium metabolism and, 510-511
- Ketoconazole, 652-654
- Kidney disease  
 diabetic nephropathy. *See Diabetic nephropathy.*  
 diabetic retinopathy correlation to, 1426-1427
- Kidney transplantation, 1069
- Labetalol, 40, 45  
 alpha-adrenergic activity of, 45  
 indications for, hypertension and, 387  
 pheochromocytoma and, 433-434  
 partial agonist activity of, 44
- Legionella pneumonia, 1074-1075
- Leukemias, 1067-1068, 1236
- Levobunolol, 66
- Lidoflazine, 84, 99
- Lipid disorders, diabetes mellitus and. *See Diabetes mellitus, lipid disorders and.*  
 normal metabolism and, 1381-1383
- Lithium, abuse of, 879  
 depression and, 816  
 childhood, 841  
 geriatric, 858-859
- Liver disease, nitrate drug therapy for, 24
- Liver transplantation, 1070
- Lorcainide, 293-294  
 antiarrhythmic effects of, 294  
 dosages for, 278, 294  
 drug interactions of, 294  
 electrophysiologic actions of, 280, 293  
 hemodynamic effects of, 280, 293-294  
 indications for, 280, 294  
 metabolism of, 278, 293  
 pharmacokinetics of, 278, 293  
 side effects of, 280, 294
- Lovastatin, 1392
- Lung disease, 434-435, 1225-1246  
 alveolar proteinosis, 1239  
 amyloidosis, 1237  
 bronchiolitis obliterans, 1235  
 bronchoalveolar lavage for, 1230-1231  
 Churg-Strauss syndrome, 1234  
 clinical presentation of, 1225-1226  
 congestive heart failure and, 1238  
 connective tissue, 1234-1235  
 cystic fibrosis, 1235-1236  
 differential diagnosis of, 1231-1241  
 drug-induced, 1232-1233

- eosinophilic granuloma, 1238-1239  
 gallium-67 scintigraphy of, 1229  
 hemorrhage and, 1237-1238  
 Hodgkin's disease, 1068, 1236  
 hypersensitivity pneumonitis, 1233  
 idiopathic fibrosis, 1240  
 infections. See *Lung infections*.  
 leukemia, 1067-1068, 1236, 1237  
 lymphangioleiomyomatosis, 1239  
 lymphocytic interstitial pneumonitis, 1236, 1237  
 lymphomas, 1236  
 lymphomatoid granulomatosis, 1236, 1237  
 metastatic cancer, 1236  
 neurofibromatosis and, 1239  
 occupational, 1233  
 plasma cell dyscrasias, 1237  
 pulmonary function tests of, 1228-1229  
 sarcoidosis and, 1233  
 vasculitis and, 1233-1234  
 Wegener's granulomatosis, 1233-1234  
 x-ray examination of, 1226-1228
- Lung infections, diagnosis of, 1070-1072**  
   bronchial brushing for, 1071  
   bronchoalveolar lavage for, 1072  
   culturing procedures for, 1070  
   open lung biopsy for, 1072-1073  
   percutaneous aspiration for, 1072  
   sputum examination for, 1070  
   transbronchial biopsy for, 1071-1072  
   transtracheal aspiration for, 1071  
 immunocompromised patients with, **1067-1069**  
   aspergillosis of, 1077-1078  
   bacterial infections of, 1073-1077  
   bone marrow transplantation and, 1068-1069  
   candidiasis of, 1079  
   cytomegalovirus of, 1079-1081  
   diagnostic tests for, 1070-1073  
   fungal infections of, 1077-1079  
   heart transplantation and, 1070  
   herpes simplex virus of, 1081  
   Hodgkin's disease and, 1068  
   kidney transplantation and, 1069  
   *Legionella* pneumonia of, 1074-1075  
   leukemia and, 1067-1068  
   liver transplantation and, 1070  
   lung transplantation and, 1070  
   mucormycosis of, 1078  
   *Mycobacteria* pneumonia of, 1076-1077  
   *Mycoplasma* pneumonia of, 1076  
   *Nocardia* pneumonia of, 1075-1076  
   non-Hodgkin's lymphoma and, 1068  
   phycomycosis of, 1078  
   *Pneumocystis carinii* pneumonia of, 1081-1082  
   protozoal infections of, 1081-1082  
   *Pseudoallescheria boydii* infection of, 1078-1079  
   toxoplasmosis of, 1082  
   varicella zoster of, 1081  
   viral infections of, 1079-1081
- Lung transplantation, 1070**  
 Lupus erythematosus 1254  
 Lymphangioleiomyomatosis, 1239  
 Lymphoma, non-Hodgkin's, 1068  
   pulmonary, 1236  
   thyroid, 1189, 1198
- Malaria, 683-688**  
   chemotherapy for, 683-688  
     8-aminoquinolone, 684, 686  
     chloroquine, 684  
     mefloquine, 687  
     proguanil, 688  
     pyrimethamine, 687-688  
     quinine, 686-687  
   etiologic of, 683  
   Maprotiline, 820  
   Mebendazole, 673-674  
   Mefloquine, 687  
   Melarsoprol, 678  
   Meprobamate, 825-826
- Mesenteric ischemia, 1091-1115**  
   anatomic considerations of, 1092-1093  
   arterial thrombosis causing, 1091, 1095  
     diagnosis of, 1096-1098  
     treatment of, 1105, 1107-1108  
   celiac artery compression and, 1110  
   chronic, 1095-1096, 1109-1110  
   classification of, 1094-1095  
   collagen vascular diseases causing, 1111  
   colonic, 1095, 1110-1111  
   diagnosis of, 1099-1105  
     abdominal ultrasound for, 1103  
     angiography for, 1091, 1101-1102  
     arterial thrombosis and, 1096-1098  
     barium studies for, 1101  
     celiac artery compression and, 1110  
     chronic ischemia and, 1109-1110  
     colonic ischemia and, 1111  
     embolism and, 1096  
     endoscopy for, 1102  
     laboratory tests for, 1091  
     leukocytosis and, 1100  
     metabolic acidosis and, 1100  
     nonocclusive ischemia and, 1098-1099  
     nuclear medicine imaging for, 1103  
     physical examination for, 1091  
     serologic tests for, 1091  
     serum enzyme analysis and, 1100  
     signs and symptoms, 1091, 1096  
     small vessel disease and, 1111-1112  
     venous thrombosis and, 1099  
     x-ray examination for, 1101  
   embolism causing, 1091, 1095  
   diagnosis of, 1096  
   treatment of, 1105, 1106

- Mesenteric ischemia (*Continued*)  
geriatric patient, 1214-1215  
metabolic abnormalities resulting from, 1094  
mortality rates for, 1091, 1092  
nonocclusive, 1095  
  diagnosis of, 1098-1099  
  treatment of, 1108-1109  
pathophysiology of, 1093-1094  
percutaneous transluminal angioplasty for, 1109  
  prognosis for, 1092  
  resuscitative measures for, 1104  
  small vessel disease causing, 1111-1112  
  surgical therapy for, 1091-1092, 1105-1108, 1110  
    bypass graft for revascularization and, 1097-1098, 1110  
    embolectomy and, 1095  
    intestinal viability assessment during, 1098  
  segmental resection of bowel and, 1091, 1097-1098  
  thrombectomy and, 1095, 1097  
treatment of, 1104-1112  
  celiac artery compression and, 1110  
  chronic ischemia and, 1110  
  colonic ischemia and, 1111  
  embolectomy, 1105, 1106  
  nonocclusive ischemia and, 1108-1109  
  papaverine infusion for, 1091, 1108-1109  
  percutaneous transluminal angioplasty for, 1109  
  results of, 1112  
  resuscitative measures for, 1104  
  segmental resection of bowel for, 1091, 1097-1098  
  small vessel disease and, 1112  
  surgical, 1091-1092, 1105-1108, 1110  
  thrombectomy, 1105, 1107-1108  
  venous thrombosis causing, 1091, 1095  
    diagnosis of, 1099  
    treatment of, 1105-1108
- Metastatic cancer, of unknown primary site, 1055-1065  
  aspiration biopsy of lymph node of, 1060-1061  
  axillary adenopathy and, 1059-1060  
  cervical lymphadenopathy and, 1060-1061  
  chemotherapy for, 1062-1063  
  common presentations of, 1056  
  computerized tomography of, 1058-1059, 1063  
  definition of, 1055  
  extragonadal germ cell tumors and, 1061-1062  
  incidence of, 1055  
  laboratory studies of, 1061, 1063  
  mammography of, 1059, 1063  
  pathologic examination of, 1056-1058, 1063  
  pelvic ultrasonography of, 1059, 1063  
  physical examination of, 1059-1061, 1063  
  x-ray examination of, 1058, 1063
- pulmonary, 1236  
thyroid gland, 1189-1190
- Methyldopa, 390
- Metoprolol, 40, 384-386  
  central nervous system effects of, 71  
  myocardial infarction drug therapy and, 60  
  pharmacokinetic properties of, 46, 48  
  Raynaud's phenomenon from, 69  
  selectivity of, 43
- Metrifonate, 683
- Metronidazole, 613-621  
  adverse effects of, 616-617  
  chemical structure of, 613, 614  
  dosages of, 618  
  drug interactions with, 617  
  indications for, 615-619  
    bacterial infections and, 615-616, 618  
    bone infections and, 619  
    central nervous system infections and, 618  
    Crohn's disease and, 619  
    endocarditis and, 619  
    gynecologic infections and, 619  
    intra-abdominal infections and, 618-619  
    joint infections and, 619  
    otitis and, 619  
    parasitic infections and, 615, 617-618  
    sinusitis and, 619  
    soft tissue infections and, 619  
  mechanism of action of, 613-614  
  parasitic infection therapy via, 675-676  
  pharmacology of, 614  
  prophylactic use of, 619  
  spectrum of activity of, 615-616
- Mexiletene, 284-286  
  antiarrhythmic effects of, 285  
  dosages for, 278, 286  
  drug interactions of, 286  
  electrophysiologic action of, 280, 285  
  hemodynamic effects of, 280, 285  
  indications for, 280, 286  
  metabolism of, 278, 285  
  pharmacokinetics of, 278, 285  
  side effects of, 280, 285-286
- Miconazole, 638-639, 648-652
- Migraine, beta-adrenergic blocker drug therapy for, 50, 65-66  
  calcium channel blockers for, 105
- Minnesota Multiphasic Personality Inventory, 911-912, 915-916
- Minoxidil, 391
- Mitral valve prolapse, beta-adrenergic blockers for, 63  
  coenzyme Q10 for, 252  
  sudden death from, 1026

- Monoamine oxidase inhibitors, depression and, 822-823  
alcoholics with, 878-879  
geriatric, 856-857  
stimulant-induced, 879  
panic disorder and, 803-804  
resistance to effects of, 904
- Monoclonal gammopathy, 1155-1167  
amyloidosis, 1163  
benign, 1164-1165  
bone scan examination of, 1161  
computerized tomography of, 1161  
laboratory procedures and tests of, 1155-1161  
beta-2 microglobulin analysis, 1158  
bone marrow examination, 1158-1159  
calcium levels, 1156-1157  
complete blood count, 1155-1156  
cryoglobulinemia analysis, 1159-1160  
flow cytometry, 1160-1161  
immunofixation techniques, 1160  
isoelectric focusing techniques, 1160  
quantitative analysis of immunoglobulins, 1158  
renal function, 1156  
serum protein electrophoresis, 1157, 1158  
serum viscosity analysis, 1159  
thymidine labeling, 1160  
urine protein electrophoresis, 1157-1158  
Western blot technique, 1160
- lymphoproliferative disorders associated with, 1164  
magnetic resonance imaging of, 1161  
of undetermined significance, 1164-1165  
plasma cell myeloma, 1161-1163  
radiographic examination of, 1161  
secondary, 1165  
Waldenström's macroglobulinemia, 1163-1164  
x-ray examination of, 1161
- Mucormycosis, 1078
- Muscular dystrophy, coenzyme Q10 for, 252
- Mycobacteria pneumonia, 1076-1077
- Mycoplasma pneumonia, 1076
- Myocardial infarction, asymptomatic, 1033, 1034  
mesenteric ischemia and, 1096  
silent myocardial ischemia and. See *Silent myocardial ischemia, myocardial infarction and.*  
sudden death from, 1022-1023
- Myocardial ischemia, silent. See *Silent myocardial ischemia.*
- Myocardial infarction, antiplatelet drugs for prevention of, 137-151  
postinfarction clinical trials of, 140-151  
primary prevention and, 137-139  
secondary prevention and, 139  
aspirin therapy for prevention of, 137-148  
postinfarction clinical trials of, 140-148  
primary prevention and, 137-139  
secondary prevention and, 139  
beta-adrenergic blockers for, 50, 60  
calcium channel blockers for, 93-94  
coronary thrombosis in etiology of, 198  
dipyridamole therapy for prevention of, 140-148  
nitrate drug therapy for, 5, 19-21  
pathogenesis of, 198  
reperfusion of ischemic myocardium for, 199-201  
coronary artery bypass surgery for, 200, 217-218  
mechanical, 200-201, 217-218  
percutaneous transluminal coronary angioplasty for, 200-201, 217-218  
pharmacologic, 200-201  
spontaneous, 199-200  
streptokinase for, 205-218  
sulfapyrazole therapy for prevention of, 148-151  
thrombolytic drug therapy for, 167, 198-199  
acylated plasminogen-streptokinase activator complex, 219-220  
streptokinase, 205-218  
tissue-type plasminogen activator, 220-221  
urokinase, 218-220  
tissue-type plasminogen activator for, 220-221  
urokinase for, 218-220
- Myocardial ischemia, coenzyme Q10 for, 243-258  
oxygen-derived free radical tissue damage in, 227-238  
allopurinol for, 233-234  
anticoagulant responses to, 231  
anti-inflammatory agents for, 236  
antineutrophilic agents for, 236  
antioxidants for, 234-236  
antiplatelet agents for, 236  
arachidonic acid metabolism in, role of, 229, 236  
beta-adrenergic blockers for, 236-237  
calcium channel blockers for, 236-237  
calcium paradox in, 232-233  
endothelial cell production of free radicals for, 230  
free radical scavengers for, 234-236  
initial damage, mechanism of, 227-230  
intracellular mechanisms of, 228-229  
irreversible damage, mechanism of, 231-233  
lipid peroxidation in, role of, 229, 235-236  
metabolites involved in, 227-228, 234-235  
neutrophil in, role of, 229-230, 236  
oxygen paradox in, 233

- Myocardial ischemia (*Continued*)  
oxygen-derived free radical tissue damage  
in, platelet reactivity to, 231  
therapeutic options for, 233-238  
thrombogenic effects of, 230-231
- Nadolol, 40, 69  
Naproxen, 128  
Neomycin, 606  
Netilmicin, 601  
Neurofibromatosis, 1239  
Neuropathy, diabetic. *See Diabetic neuropathy.*  
Neurotransmitters, depression and. *See Depression, neurotransmitter hypothesis of.*  
Nicardipine, 84, 481-485  
hemodynamic effects of, 482-483  
indications for, angina pectoris and, 485  
hypertension and, 483-485  
sustained-release, 483-485  
therapeutic effects of, 483-485  
combination therapy and, 483  
open studies of, 483  
placebo-controlled trials on, 483  
Niclosamide, 675  
Nicotinic acid, 1392  
Nifedipine, 84, 456-463  
animal studies of, 455  
antiplatelet activity of, 134-135  
dosages for, 87  
electrophysiologic effects of, 88-89, 99-100  
hemodynamic effects of, 89-90, 456  
indications for, angina pectoris and, 91-93, 188-189, 192-193, 463  
asthma and, 103  
congestive heart failure and, 97  
esophageal spasm and, 104  
hypertension and, 95-96, 387-388, 457-463  
hypertensive crisis and, 460-463  
hypertrophic cardiomyopathy and, 98  
migraine and, 105  
myocardial infarction and, 94  
myocardial ischemia and, 188-189, 192-193  
myometrial hyperactivity and, 104  
pulmonary hypertension and, 101-102  
Raynaud's phenomenon and, 103-104, 261-262  
mechanism of action of, 450  
pharmacokinetic properties of, 84-87  
renin activity and, 457  
structure of, 449-450  
sustained-release, 459-460  
therapeutic effects of, 457-459  
combination therapy and, 458-459  
monotherapy and, 457-458  
vasodilator action of, 452
- Nifurtimox, 679  
Niludipine, 84  
Nimodipine, 84  
Nimodipine, 104-105  
Nisoldipine, 84  
Nitrates, 1-35  
anesthesia with, 23  
antiplatelet activity of, 133  
coronary effects of, 8-12  
delivery systems for, 3  
dermal, 26-28  
formulations of, 24-29  
historical background of, 1-2  
indications for use of, 2-3, 13-24, 30-31  
anginal syndromes and. *See Angina pectoris, nitrate drug therapy for.*  
cirrhosis of liver and, 24  
congestive heart failure and, 21-23  
esophageal disease and, 24  
myocardial infarction and, 5, 19-21  
myocardial ischemia and, 186-188  
portal hypertension and, 24  
pulmonary hypertension and, 23  
intracellular actions of, 5-7  
isosorbide dinitrate and. *See Isosorbide dinitrate.*  
5-isosorbide mononitrate and, 3, 26, 30  
long-acting, 15-16, 26-28  
mechanism of action of, 4-7  
modulators of effects of, 12  
nitroglycerin and. *See Nitroglycerin.*  
recommendations regarding usage of, 30-31  
resurgence of, 2-3  
short-acting, 24-26  
side effects of, 29  
systemic effects of, 7-8  
tolerance to, 3-4, 29-30  
topical, 26-28  
vascular effects of, 7-12  
Nitrendipine, 476-481  
hemodynamic effects of, 476-479  
metabolic effects of, 476-479  
therapeutic effects of, 479-481  
combination therapy and, 481  
comparative analysis of, 480-481  
monotherapy and, 479-480  
Nitroglycerin, 1-2  
anesthesia with, 23  
antiplatelet activity of, 133  
buccal, 24, 26  
coronary effects of, 8-11  
formulations of, 24-28  
historical background of, 1-3  
indications for use of, angina pectoris and, 13-19, 186  
congestive heart failure and, 22-23  
myocardial infarction and, 19-21  
myocardial ischemia and, 186-187  
Raynaud's phenomenon and, 262

- mechanism of action of, 4-6
- modulators of effects of, 12
- oral spray, 15, 24
- side effects of, 29
- sublingual, 12-15, 20, 24
- systemic effects of, 7
- tolerance to, 4, 29
- transdermal, 3, 4, 15, 23, 28
- transmucosal, 3, 24, 26
- Nivadipine, 489
- Nocardia pneumonia, 1075-1076
- Non-Hodgkin's lymphoma, 1068
- Norfloxacin, adverse effects of, 629-630
  - chemistry of, 623
  - indications for, 630-632
    - diarrheal disease and, 632
    - gastritis and, 633
    - respiratory infections, 632
    - sexually transmitted diseases and, 631
    - skin infections and, 633
    - urinary tract infection and, 630
  - pharmacology of, 627-629
  - prophylactic use of, 634
  - resistance to, 625
  - spectrum of activity of, 625-627
- Nylidrin, 259-260
- Obsessive-compulsive disorder, 746, 759-760
- Oculomucocutaneous syndrome, beta-adrenergic blocker-induced, 72
- Ofloxacin, adverse effects of, 629-630
  - chemistry of, 623
  - indications for, 630-632
    - diarrhea and, 632
    - osteomyelitis and, 633
    - respiratory infections and, 632
    - skin infections and, 633
    - urinary tract infections and, 630
  - pharmacology of, 627-629
  - resistance to, 625
  - spectrum of activity of, 625-627
- Opiates, abuse of, anxiety disorder associated with, 877
  - depression from, 875, 880
  - mood changes from, 872
- Oral hypoglycemic agents, 1323-1335
  - biguamides, 1330-1331
  - future research on, 1331-1332
  - sulfonylurea derivatives, 1323-1330
    - absorption of, 1325
    - adverse effects of, 1328-1330
    - cardiovascular effects of, 1328-1329
    - comparative analysis of, 1358
    - dermatologic effects of, 1330
    - distribution of, 1325
    - dosages for, 1328
    - drug interactions of, 1330
    - efficacy of, 1325-1328
    - elimination of, 1325
    - hypoglycemia as adverse effect of, 1328
    - hyponatremia as adverse effect of, 1329-1330
    - indications for, 1358-1359
    - insulin therapy combined with, 1363
    - mechanism of action of, 1323-1325
    - metabolism of, 1325
    - pharmacokinetic properties of, 1325
    - selection of drug, criteria for, 1358
- Osteomyelitis, antibiotic therapy for, 723-738
  - adverse reactions to, 733-734
  - aminoglycoside, 732, 736
  - bacteriology and, 731-732, 735-736
  - cephalosporin, 732, 736
  - chronic infection and, 736
  - clindamycin, 732, 736
  - contiguous septic focus of infection and, 727-728, 734-735
  - hematogenous dissemination of infection and, 725-727, 734-735
  - intravenous administration of, 736-737
  - materials and methods of study of, 723-724
  - oral administration of, 737
  - prognosis for, 735-736
  - prosthetic device infection and, 730-731, 735
  - quinolone, 633, 737
  - results of study of, 724-734
  - vascular insufficiency and, 728-730, 735
- Overanxious disorder, 757
- Oxprenolol, 40
- Oxygen free radicals, 227
  - ischemic myocardial injury from. See *Myocardial ischemia, oxygen-derived free-radical tissue damage in.*
- Pancreatic cancer, 979-992
  - alcohol use and, 983
  - bile and duodenal contents reflux and, 982
  - caffeine consumption and, 983
  - causes of, 981-983
  - cigarette smoking and, 983
  - diabetes mellitus and, 981
  - diagnosis of, 985-990
    - computerized tomography, 988-990
    - endoscopic retrograde pancreatography, 988-990
    - immunologic tests for, 986-988
    - laboratory tests for, 985-988
    - magnetic resonance imaging, 989
    - noninvasive pancreatic function tests for, 989
    - timing of, 979
    - ultrasonography, 988-990
    - x-ray examination, 986

- Pancreatic cancer** (*Continued*)  
 diet and, 983  
 environmental factors predisposing to, 982-983  
 epidemiology of, 979, 981  
 pancreatitis predisposing to, 981-982  
 papillary epithelial hyperplasia and, 982  
 tumor markers for, 986-988
- Pancreatitis, 979-992**  
 alcohol intake and, 979-981, 1146  
 cancer resulting from, 981-982  
 causes of, 979-981  
 cigarette smoking and, 981  
 cyanide toxicity and, 981  
 diagnosis of, 983-985  
   computerized tomography, 984-985  
   endoscopic retrograde pancreatography, 984-985  
   laboratory tests for, 984  
   timing of, 979  
   ultrasonography, 984-985  
   x-ray examination, 984  
 diet and, 980-981  
 epidemiology of, 979  
 geriatric patient, 1216
- Panic disorders, 746**  
 alcoholism and, 876, 878-879  
 basal state differences in, 799  
 biologic basis for, 798-807  
   correlational studies of, 798-800  
   provocative studies of, 800-803  
   suppressive studies of, 803-805  
 cerebral metabolism with, 799  
 cocaine abuse and, 877  
 diagnosis of, 758-759  
 neuroendocrine changes with, 798-800  
 opiate abuse and, 877  
 pharmacodynamic changes with, 798-799  
 physiologic changes with, 798-800  
 provocative agents causing, 800-803  
   caffeine and, 802  
   carbon dioxide inhalation and, 801-802  
   hypoglycemia and, 802  
   insulin and, 802  
   isoproterenol and, 801  
   lactate infusion and, 800-801  
   norepinephrine and, 801  
   opioid blockade and, 802  
   yohimbine and, 802  
 suppressive agents for, 803-805  
   benzodiazepines and, 804-805  
   buspirone and, 805  
   monoamine oxidase inhibitors and, 803-804  
   propranolol and, 805  
   serotonin reuptake inhibitors and, 804  
   trazodone and, 805  
   tricyclic antidepressants and, 803-804  
 temporal ictal phenomenon and, 806-807
- Papaverine, 259**
- Parasitic infections, antimicrobial agents for, 672-688**  
 albendazole, 674-675  
 8-aminoquinolones, 684, 686  
 chloroquine, 684  
 diethylcarbamazine citrate, 679  
 emetine, 677  
 furazolidine, 677-678  
 iodoquinol, 675  
 ivermectin, 680-681  
 mebendazole, 673-674  
 mefloquine, 687  
 melarsoprol, 678  
 metrifonate, 683  
 metronidazole, 675-676  
 niclosamide, 675  
 nifurtimox, 679  
 paromomycin, 676-677  
 pentamidine isethionate, 681-683  
 praziquantel, 672-673  
 proguanil, 688  
 pyrantel pamoate, 678  
 pyrimethamine, 687-688  
 quinacrine hydrochloride, 676  
 quinine, 686-687  
 stibogluconate sodium, 679-680  
 suramin, 678-679  
 thiabendazole, 674  
 trichlorfon, 683  
 epidemiology of, 669-671  
 pathogenicity of, 671-672
- Paromomycin, 676-677**
- Paroxysmal supraventricular tachycardia, beta-adrenergic blockers for, 58**
- Pefloxacin, chemistry of, 623**  
 pharmacology of, 627-629
- Pelvic abscess, 1251**
- Penbutolol, 40**
- Pentamidine isethionate, 681-683**
- Pentoxifylline, antiplatelet activity of, 136**  
 intermittent claudication therapy and, 260-261
- Peptic ulcer, geriatric patient 1216-1217**
- Percutaneous transluminal coronary angioplasty, 166**  
 antiplatelet drug therapy after, 166-167  
 reperfusion of ischemic myocardium through, 200, 217-218  
 restenosis after, 166
- Perinephric abscess, 993-1014**  
 anatomical considerations of, 994-995, 999-1000  
 bacteria causing, 996-999, 1010  
 cause of, 993  
 definition of, 993  
 diabetes mellitus and, 1000-1001  
 diagnosis of, 1001-1008  
   computerized tomography, 1005-1008  
   intravenous pyelography, 1004  
   laboratory tests for, 1002-1003



- misdiagnosis, 993-994
- physical examination for, 1002
- radioisotopic scanning, 1008
- signs and symptoms, 1001-1002
- ultrasonography, 1004-1005
- x-ray examination, 1003-1004
- fever of, 1251
- hematogenous seeding of bacteria predisposing to, 993, 996-997
- historical background of, 993
- immunosuppression and, 1001
- incidence of, 993
- mortality rates for, 993
- pathogenesis of, 994-997
- polycystic kidney disease and, 1000
- traumatic injury and, 1000
- treatment of, 993, 1008-1012
  - antibiotic therapy, 1010
  - cyst aspiration, 1010-1012
  - incision and drainage, 1008-1009
  - nephrectomy for, 1009
  - recurrence after, 1012
- ureteral reflux and, 999-1000
- urinary tract infections and, 993, 996-997, 999-1000
- Peripheral nervous system, diabetes mellitus effect on. *See Diabetic neuropathy.*
- organization of, 1440-1442
- Phenoxylbenzamine, dosages for, 435
- indications for, congestive heart failure and, 432
  - hypertension and, 386-387
  - pheochromocytoma and, 433
- pharmacokinetics of, 435-436
- Phentolamine, dosages for, 435
- indications for, arrhythmias and, 433
- congestive heart failure and, 431-432
- hypertension and, 386-387
- pheochromocytoma and, 433
- pulmonary hypertension and, 434-435
- pharmacokinetics of, 435
- side effects of, 435-436
- Pheochromocytoma, 433-434
- Phobias, 746
  - alcoholism and, 876, 879
  - diagnosis of, 758
  - epidemiology of, 868
  - opiate abuse and, 877
  - social, 759
- Phospholipase inhibitors, 127-128
- Phosphonoformic acid, 708
- Phycomycosis, 658, 1078
- Pinacidil, 391
- Pindolol, 40
  - angina pectoris drug therapy and, 189
  - myocardial ischemia drug therapy and, 189
  - partial agonist activity of, 44-45
  - potency of, 40
  - Raynaud's phenomenon from, 69
- Pirmenol, 282-283
  - antiarrhythmic effects of, 282
  - dosages for, 278, 283
  - drug interactions of, 283
  - electrophysiologic action of, 280, 282
  - hemodynamic effects of, 280, 282
  - indications for, 280, 283
  - metabolism of, 278, 282
  - pharmacokinetics of, 278, 282
  - side effects of, 280, 282-283
- Plasma cell myeloma, 1161-1163
  - diagnosis of, 1161-1163
  - indolent, 1162-1163
  - localized plasma cell tumors vs, 1163
  - pulmonary infiltrates of, 1237
  - smouldering, 1162-1163
  - staging system for, 1162
- Platelet-derived growth factor, 125
- Platelets, 117-127
  - adhesion of, 118-120
  - aggregation of, 120
  - antiplatelet drugs and. *See Antiplatelet drugs.*
  - aortocoronary bypass surgery failure and, 158
  - atherogenesis and, 124-126
  - blood vessel antithrombotic properties and, 122
  - clotting mechanism activation by, 120-124
  - cyclo-oxygenase inhibitor effect on, 128-130
  - measurements of activity of, 121-122
  - oxygen-derived free radical damage to myocardium and, 231
  - phospholipase inhibitor effect on, 127-128
  - properties of, 117-124
  - prostacyclin interaction with, 122-124
  - thromboxane A<sub>2</sub> synthesis by, 122-124
  - thromboxane synthetase inhibitor effect on, 130-131
- Pneumocystis carinii* pneumonia, 1081-1082
- Pneumonia, aspergillosis, 1077-1078
  - candidiasis, 1079
  - cytomegalovirus, 1079-1081
  - herpes virus, 1081
  - Legionella*, 1074-1075
  - mucormycosis, 1078
  - Mycobacteria*, 1076-1077
  - Mycoplasma*, 1076
  - Nocardia*, 1075-1076
  - Pneumocystis carinii*, 1081-1082
  - Pseudallescheria boydii*, 1078-1079
  - toxoplasmosis, 1082
  - varicella zoster, 1081
- Portal hypertension, 24
- Post-traumatic stress disorder, 760-761
- Practolol, 72
- Praziquantel, 672-673
- Prazosin, indications for, angina pectoris and, 432-433
  - arrhythmia and, 433

Prazosin (*Continued*)

- indications for, bronchospasm and, 434
- congestive heart failure and, 432
- hypertension and, 386-387, 430-431
- Raynaud's phenomenon and, 262
- pharmacokinetics of, 436
- side effects of, 436
- Pregnancy, diabetic mellitus and. *See Diabetes mellitus, pregnancy and.*
- Premature ventricular contractions, beta-adrenergic blockers for, 59
- Probucol 1392
- Prolactin, depression and, 774-775
- Propafenone, 294-297
  - antiarrhythmic effects of, 296
  - dosages for, 278, 297
  - drug interactions of, 297
  - electrophysiologic action of, 280, 295
  - hemodynamic effects of, 280, 295-296
  - indications for, 280, 297
  - metabolism of, 278, 295
  - pharmacokinetics of, 278, 295
  - side effects of, 280, 296-297
- Propranolol, 40, 384-386
  - antiplatelet activity of, 131-133
  - central nervous system effects of, 71
  - congestive heart failure from, 67
  - drug interactions of, 72
  - geriatric use of, issues of, 49
  - indications for usage of, 40
    - alcohol withdrawal and, 39
    - angina pectoris and, 188-189
    - arrhythmia and, 59
    - dissecting aneurysm and, 63
    - essential tremor and, 67
    - glaucoma and, 66
    - hypertrophic cardiomyopathy and, 62
    - migraine prophylaxis and, 65
    - myocardial infarction and, 60
    - myocardial ischemia and, 188-189
    - Q-T interval prolongation syndrome and, 63
    - thyrotoxicosis and, 64
  - membrane-stabilizing activity of, 43
  - peripheral vascular effects of, 69
  - pharmacokinetic properties of, 46, 48
  - Raynaud's phenomenon from, 69
  - ventilatory effects of, 69
- Proquanal, 688
- Prostacyclin, 122-124
  - antianginal activity of, 153
  - antiplatelet activity of, 131
  - coronary artery disease and, 126
  - coronary artery recanalization and, 167
- Prostatic abscess, 1252
- Prostatic obstruction, 435
- Pseudallescheria boydii*, 656, 1078-1079
- Psychogenic fever, 1248
- Psychotherapy, anxiety disorder therapy via, 917-918, 920-922
  - approach-withdrawal theory for, 918
  - avoidance theories for, 917-918
  - cognitive theories for, 917-918
  - combination drug therapy with, 921-922
    - comparative analysis of, 921
    - drug therapy vs, 921-922
    - effectiveness of, 920-922
    - no therapy vs, 920-921
    - respondent theories for, 917
  - depression therapy via, 918-920, 922-924
  - behavioral theory for, 920
  - childhood disorders and, 842-843
  - cognitive theories for, 918-919
  - combination drug therapy with, 923-924
    - drug therapy vs, 923
    - effectiveness of, 922-924
    - Rehm's self-control theory for, 919
- Pulmonary hypertension, drug therapy for, 434-435
  - calcium channel blockers, 101-102
  - nitrates, 23, 30
- Pulmonary infections. *See Lung infections.*
- Pyrantel pamoate, 678
- Pyrazinamide, 664
- Pyridinolcarbamate, 152
- Pyrimethamine, 687-688
- Q-T interval prolongation syndromes, beta-adrenergic blocker drug therapy for, 63
- Quinacrine hydrochloride, 676
- Quinine, 686-687
- Quinolones, 623-636
  - adverse effects of, 629-630
  - chemistry of, 623-624
  - indications for, 630-633
    - cystic fibrosis and, 632
    - diarrheal diseases and, 632-633
    - gastritis and, 633
    - osteomyelitis and, 633
    - respiratory infections and, 632
    - sexually transmitted disease and, 631
    - skin infections and, 633
    - urinary tract infections and, 630-631
  - mechanism of action of, 623-624
  - pharmacology of, 627-629
  - prophylactic use of, 633-634
  - resistance to, 624-625
  - spectrum of activity of, 625-627
- Raynaud's phenomenon, drug therapy for, 261-262, 435
  - beta-adrenergic blockers and, 69
  - calcium channel blockers for, 103-104
  - management of, 261-262
- Renal disease. *See Kidney disease.*
- Reserpine, 262, 390-391
- Rheumatic fever, 1252-1253
- Rheumatoid arthritis, 1254

- Ribavirin, 698-700, 707  
administration of, routes of, 699-700  
dosages for, 699-700  
indications for, 699  
mechanism of action of, 698  
pharmacokinetics of, 698  
side effects of, 698-699  
spectrum of activity of, 698  
toxicity of, 698-699
- Rifampin, 663-664
- Rimantadine, 704
- Rorschach test, 911, 912
- Sarcoid, 1255
- Sarcoidosis, 1233
- Sedatives, abuse of, anxiety disorder associated with, 877  
depression from, 875  
mood changes from, 872
- Separation anxiety disorder, 757
- Serotonin, 501-505  
cardiovascular effects of, 501-504  
hypertension and, 504-505  
ketanserin as antagonist to, 505  
mechanism of action of, 502-504  
structure of, 501
- Shock, drug therapy for, 434
- Silent myocardial ischemia, 1033-1054  
ambulatory ECG monitoring of, 1033, 1036-1039  
angina pectoris and, 1036-1038  
positron emission tomographic studies and, 1036, 1038  
prognostic implications of, 1037-1038  
ST segment depression in, 1033-1034, 1036-1039  
treadmill testing vs, 1037  
validation of, 1036-1037
- angina pectoris and, 1035  
ambulatory ECG of, 1035, 1037-1039  
exercise ECG test of, 1039  
radionuclide left ventriculographic stress test of, 1042  
sudden death from, 1043-1044  
thallium-201 perfusion stress test of, 1041
- aortic stenosis and, 1034
- autonomic nervous system in, role of, 1035, 1045  
clinical evaluation of, 1047-1048
- coronary artery disease and, 1033, 1034  
ambulatory ECG monitoring of, 1037-1039  
exercise ECG test of, 1039-1040  
radionuclide left ventriculographic stress test of, 1042  
sudden death from, 1043-1044  
thallium-201 perfusion stress test of, 1041
- drug therapy for, 1045-1048  
aspirin, 1046-1047  
beta-adrenergic blocker, 1045-1046  
calcium channel antagonist, 1046  
nitrate, 1046
- endorphins in, role of, 1045
- exercise ECG test for, 1033, 1039-1041
- incidence of, 1034
- myocardial infarction and, 1033, 1034  
ambulatory ECG monitoring of, 1037, 1039  
exercise ECG test of, 1039, 1041  
radionuclide left ventriculographic stress test of, 1042-1043  
sudden death from, 1043-1044  
thallium-201 perfusion stress test of, 1041-1042
- pain perception threshold in, 1044-1045
- pathophysiologic mechanisms of, 1034-1036
- positron emission tomographic studies of, 1036, 1038
- radionuclide left ventriculographic stress test of, 1042-1043
- risk factor modification for treatment of, 1047
- sudden death from, 1037, 1043-1044  
exercise ECG test predictive of, 1039  
risk evaluation for, 1043-1044  
ventricular arrhythmias causing, 1043
- thallium-201 perfusion stress test of, 1033, 1041-1042  
treatment of, 1045-1048
- Sinus tachycardia, beta-adrenergic blockers for, 58
- Sleep studies, depression and, 775-776
- Sotalol, 57, 67, 301-302  
antiarrhythmic effects of, 301  
dosages for, 279, 302  
drug interactions of, 302  
electrophysiologic action of, 281, 301  
hemodynamic effects of, 281, 301  
indications for, 281, 302  
metabolism of, 279, 301  
pharmacokinetics of, 279, 301  
side effects of, 281, 301-302
- Sporotrichosis, drug therapy for, 654
- Stibogluconate sodium, 679-680
- Stimulants, abuse of, anxiety disorders associated with, 877  
depression associated with, 874-875  
mood changes from, 871-872
- Streptokinase, 205-218  
acylated plasminogen streptokinase activator complex, 203-205, 219-220  
clinical studies of, 205-218  
complications of, 210-212  
criteria for patient selection in, 205-206  
determinant factors of outcome in, 212-213  
follow up treatment in, 216-218

- Streptokinase** (*Continued*)  
 clinical studies of, intracoronary vs intravenous administration in, 206-207  
 left ventricular function in, 208-210  
 myocardial salvage in, 208-210  
 protocol for administration in, 207-208  
 reperfusion results in, 208-210  
 results of, 213-216  
 historical background of, 205  
 indications for use of, myocardial infarction and, 205-218  
 thromboembolic disease and, 263  
 site of action of, 203
- Streptomycin**, 600, 664
- Substance abuse**, 867-885  
 alcoholism and. See *Alcoholism*.  
 anxiety disorders from, 867  
 alcoholism and, 875-877  
 benzodiazepine abuse and, 877  
 clinical presentation of, 867  
 cocaine abuse and, 877  
 comorbidity of, 869  
 opiate abuse and, 877  
 sedative abuse and, 877  
 stimulant abuse and, 877  
 treatment of, 878-880
- depression from, 867  
 alcoholism and, 872-874  
 benzodiazepine abuse and, 875  
 clinical presentation of, 867  
 comorbidity of, 869  
 opiate abuse and, 875  
 sedative abuse and, 875  
 stimulant abuse and, 874-875  
 treatment of, 878-881
- drug abuse and. See *Drug abuse*.  
 epidemiology of, 868-870  
 mood changes from, 871-872  
 psychopathology associated with, 870-871  
 suicidal behavior and, 945
- Sudden cardiac death**, 1015-1031  
 aborted, 1023-1024  
 aortic stenosis and, 1026  
 athletes with predisposition to, 1025-1026  
 autonomic nervous system in, role of, 1019  
 bereavement and, 1019  
 cardiomyopathy causing, 1025  
 coronary artery disease and, 1015-1016  
 definition of, 1015  
 electrophysiologic testing of survivors of, 1024  
 exercise precipitating, 1025  
 mitral valve prolapse and, 1026  
 myocardial infarction and, 1022-1023  
 myocardial ischemia and. See *Myocardial ischemia, sudden death and*.  
 personality types associated with, 1018  
 predictive ECG for, resting ECG, 1019-1020  
 signal averaged, 1024-1025
- psychosocial factors predisposing to, 1018-1019  
 race as factor in, 1017-1018  
 sex as factor in, 1018  
 signs and symptoms of, 1016-1017  
 socioeconomic factors associated with, 1017  
 stress and, 1018-1019  
 ventricular arrhythmias of, 1021-1022
- Suicidal behavior**, 937-971  
 affective disorders and, 943-944  
 AIDS and, 951  
 alcoholism and, 945  
 biologic factors correlated to, 952-953  
 cancer and, 950  
 clinical management of, 955-957  
 drug therapy in, 957  
 hospitalization for, 958  
 interventions in, 957-960  
 outpatient therapy for, 958  
 psychological aspects of, 956-957  
 depression and, 841, 944-945  
 diagnosis of, 953-955  
 drug abuse and, 945  
 educational programs on, 960, 962  
 environmental factors correlated to, 948-949  
 epidemiology of, 938-939  
 epilepsy and, 950  
 family history of, 951-952  
 genetics of, 951-952  
 geriatric depression and, 860  
 medical illness associated with, 949-950  
 peptic ulcers and, 950  
 personality traits/disorders associated with, 946-948  
 prevention of, 960  
 psychiatric diagnosis correlated to, 943-946  
 psychological explanations for, 940-941  
 psychosocial factors correlated to, 948-949  
 risk factors for, 941-953  
 biologic factors as, 952-953  
 environmental factors as, 948-949  
 family history and, 951-952  
 genetics and, 951-952  
 medical illness and, 949-951  
 overlap model of, 941-943  
 personality traits/disorders and, 946-948  
 psychiatric diagnosis and, 943-946  
 psychosocial factors as, 948-949  
 schizophrenia and, 945-946  
 sociocultural explanations for, 940-941  
 substance abuse and, 945  
 threshold model for, 960-961
- Sulfinpyrazone**, 128  
 antiplatelet activity of, 169-170  
 indications for use of, angina pectoris and, 155-156

- aortocoronary bypass graft patency maintenance and, 162, 165
- coronary angioplasty restenosis prevention and, 166
- myocardial infarction prevention and, 148-151
- mechanism of action of, 130
- Sulfonylurea drugs. *See Oral hypoglycemic agents, sulfonylurea derivatives.*
- Supraventricular arrhythmias, beta-adrenergic blockers for, 57-59
- calcium channel blockers for, 100-101
- Supraventricular ectopic beats, beta-adrenergic blockers for, 58
- Suramin, 678-679, 707
- Temporal arteritis, 1254
- Teprotide, 399-400
- Terazosin, 441-448
  - adverse reactions to, 445-446
  - clinical studies of, 443-444
  - comparative analysis of, 441-443
  - dosages for, 436, 446
  - hemodynamic effects of, 441-442
  - indications for, 443-444
  - mechanism of action of, 441-443
  - metabolism of, 443
  - pharmacokinetics of, 436
  - serum lipids affected by, 444-445
- Tetralogy of Fallot, beta-adrenergic blocker drug therapy for, 63
- Thematic Apperception test, 911, 913
- Thiabendazole, 674
- Thiacetazone, 664
- Thienamycin, 567-568
- Thromboembolic disease, drug therapy for, 262-264
- Thrombolysis, 202-205
- Thrombolytic therapy, 197-226
  - anticoagulant drug therapy with, 167
  - antiplatelet drug therapy with, 167
  - myocardial infarction management with, 198-199
    - pathogenesis of disease and, 198
    - pharmacologic reperfusion for, 201
    - rationale for, 198-199
  - sites of action of agents in, 203-205
  - streptokinase in. *See Streptokinase.*
  - thromboembolic disease and, 263
  - thrombolysis and, 202-205
  - tissue-type plasminogen activator in, 220-221
  - urokinase in, 218-220
- Thromboxane, 122-124, 126
- Thromboxane synthetase inhibitors, 130-131, 153
- Thrombus formation, 117-119
- Thyroid carcinoma, 1177
  - anaplastic, 1189
  - cytologic examination of, 1197-1199
  - differential diagnosis of, 1182, 1184-1189
  - epidemiology of, 1179-1182
  - fine-needle aspiration biopsy of, 1196-1199
  - follicular, 1187
  - medullary, 1187-1189
  - papillary, 1184-1187
  - prevalence of, 1178-1182
  - secondary, 1189-1190
  - treatment of, 1200
- Thyroid function tests, 1192
- Thyroid gland, adenoma of, 1183
  - diagnosis of, 1183-1184
  - treatment of, 1200-1201
- carcinoma of. *See Thyroid carcinoma.*
- cysts of, 1182
  - diagnosis of, 1182, 1183
  - treatment of, 1200
- nodules of. *See Thyroid nodules.*
- Thyroid nodules, 1177-1211
  - adenomas and, 1183-1184, 1200, 1201
  - age correlation to, 1178, 1190
  - blood tests of, 1192-1193
  - cancer and. *See Thyroid carcinoma.*
  - colloid, 1183
  - cysts and, 1182, 1183, 1200
  - diagnosis of, 1182-1201
    - biochemical markers for, 1192-1193
    - calcitonin analysis, 1192-1193
    - differential, 1182-1190
    - fine-needle aspiration biopsy for, 1196-1199
    - laboratory tests for, 1192-1193
    - medical history for, 1190-1191
    - physical examination for, 1191-1191
    - radionuclide imaging for, 1195-1196
    - sequencing of tests for, 1199
    - thyroid function tests for, 1192
    - thyroid hormone suppression tests for, 1194-1195
    - ultrasound, 1193-1194
    - x-ray examination for, 1193
- differential diagnosis of, 1182-1190
- adenoma and, 1183-1184
- autonomously functioning thyroid nodules and, 1184
- carcinoma and, 1184-1189
- colloid nodules and, 1183
- cysts and, 1182-1183
- lymphoma and, 1189
- metastatic cancer and, 1189-1190
- exposure to ionizing radiation and, 1178, 1191
- family history of, 1191

Thyroid nodules (*Continued*)

- fine-needle aspiration biopsy of, 1196–1199
  - accuracy of, 1196, 1197
  - complications of, 1198–1199
  - cost effectiveness of, 1199
  - false positive cytology from, 1198
  - follow up procedures for, 1198
  - frozen section vs, 1199
  - hyperfunctioning nodules and, 1198
  - indeterminate cytology from, 1197–1198
  - lymphoma and, 1198
  - repeat procedures of, 1198
  - sampling errors of, 1196–1197
- laboratory tests of, 1192–1193
- medical history of, 1190–1191
- prevalence of, 1178
- radionuclide imaging of, 1195–1196
- sex correlation to, 1190
- single vs multiple, 1192
- treatment of, 1200–1201
  - adenomas and, 1200, 1201
  - benign multinodular euthyroid goiter and, 1200–1201
  - cancer and, 1200
  - cysts and, 1200
  - ultrasonography of, 1193–1194
  - x-ray examination of, 1193
- Thyroiditis, 1255
- Thyrototoxicosis, beta-adrenergic blocker drug therapy for, 39, 50, 64–65
- Ticlopidine, 135
  - antianginal activity of, 153
  - aortocoronary bypass graft patency maintenance with, 163
  - coronary angioplasty restenosis prevention with, 166
- Timolol, 40, 384–386
  - congestive heart failure from, 67
  - indications for use of, glaucoma and, 66
  - myocardial infarction and, 60
  - structure-activity relationship of, 40–41
- Tiopamil, 84
- Tissue plasminogen activator, 220–221
  - development of, 220
  - myocardial infarction drug therapy and, 221
  - site of action of, 203–204
- Tobramycin, 601
- Tocainide, 283–284
  - antiarrhythmic effects of, 284
  - dosages for, 278, 284
  - drug interactions of, 284
  - electrophysiologic action of, 280, 283
  - hemodynamic effects of, 280, 284
  - indications for, 280, 284
  - metabolism of, 278, 283–284
  - pharmacokinetics of, 278, 283–284
  - side effects of, 280, 284
- Tolazoline, 259–260

## Topical antibiotics, antifungal, 637–643

- ciclopirox olamine, 638
- haloprogin, 637–638
- miconazole, 638–639
- side effects of, 639
- ocular infection therapy via, 717–721
  - bacteriology and, 718–719
  - intravitreal therapy vs, 719, 720
  - pharmacokinetics of, 717–718
  - recommendations for, 720–721
  - subconjunctival therapy vs, 719, 720
  - systemic therapy vs, 719, 720
- Toxoplasmosis, 1082
- Transplants, bone marrow, 1068–1069
  - heart, 1070
  - kidney, 1069
  - liver, 1070
  - lung, 1070
- Trazodone, 805, 821
- Tremor, beta-adrenergic blocker drug therapy for, 50, 67
- Trichlorfon, 683
- Tricyclic antidepressants, depression and, 816–820
  - alcoholics with, 878–879
  - childhood, 841–842
  - geriatric, 853–856
  - substance abuse-induced, 879–880
  - panic disorder and, 803–804
- Trimazosin, indications for, congestive heart failure and, 432
- hypertension and, 431
- Tuberculosis, 1252
  - drug therapy for, 661–667
    - cycloserine, 664
    - effectiveness of, 666–667
    - ethambutol, 664
    - ethionamide, 664
    - isoniazid, 662–663
    - prophylactic, 664–666
    - pyrazinamide, 664
    - regimens for, 666–667
    - rifampin, 663–664
    - streptomycin, 664
    - thiacetazone, 664
  - transmission of, 661
- Typhoid fever, 1253
- Ulcer of Dieulafoy, 1172–1173
- Ulcerative colitis, 1255
- Urinary tract infection, geriatric patient, 1221
- Urokinase, 218–220
  - disadvantages of, 218
  - indications for use of, myocardial infarction and, 218–219
  - thromboembolic disease and, 263
  - mechanism of action of, 204
  - single-chain, 203, 204, 220
  - site of action of, 203

- Varicella zoster, 1081
- Vascular ectasias, 1171, 1172
- Vasculitis, fever of, 1253-1254
- pulmonary, 1233-1234
- Vasodilator drugs, calcium channel blockers as, 452
- hypertension therapy with, 391
- intermittent claudication therapy with, 259-261
- nitrates as. See *Nitrates*.
- Ventricular arrhythmias, beta-adrenergic blockers for, 59
- calcium channel blockers for, 101
- Ventricular ectopic beats, beta-adrenergic blockers for, 59
- Ventricular fibrillation, beta-adrenergic blockers for, 59
- Ventricular tachycardia, beta-adrenergic blockers for, 59
- Verapamil, 84, 305-308, 463-468
- antiplatelet activity of, 134
- dosages for, 88, 279, 307-308
- drug interactions of, 307, 485
- electrophysiologic effects of, 88-89, 99-100, 281, 305-306
- hemodynamic effects of, 89-90, 281, 306, 463
- indications for, 281, 307-308
- angina pectoris and, 91-93, 188-192, 468
- aortocoronary bypass graft patency maintenance and, 159-163
- arrhythmia and, 100-101, 306-307
- asthma and, 103
- congestive heart failure and, 97
- coronary angioplasty restenosis prevention and, 166
- hypertension and, 95-96, 387-388
- hypertensive crisis and, 468
- hypertrophic cardiomyopathy and, 98-99
- migraine and, 105
- myocardial infarction and, 94
- myocardial ischemia and, 188-192
- pulmonary hypertension and, 102
- Raynaud's phenomenon and, 103-104
- thromboembolic disease with, 262-264
- mechanism of action of, 450-451
- metabolism of, 279, 306
- pharmacokinetic properties of, 84-87, 279, 306
- side effects of, 281, 307
- structure of, 449-450
- therapeutic effect of, 463-468
- combination therapy and, 467
- comparative analysis of, 464-467
- monotherapy and, 463-464
- vasodilator action of, 452
- Vidarabine, 700-702
- adverse reactions of, 701
- dosages for, 702
- indications for, 701-702
- mechanism of action of, 700-701
- pharmacokinetics of, 701
- spectrum of activity of, 700
- toxicity of, 701
- Viral infections, AIDS and. See *AIDS*.
- drug therapy for. See *Antiviral agents*.
- Virucidal tissue paper, 711
- Waldenstrom's macroglobulinemia, 1163-1164
- Wegener's granulomatosis, 1233-1234, 1236-1237
- Whipple's disease, 1255
- WIN compounds, 711